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Abstract 
 
Regulation of gene expression comprises a wide range of mechanisms that 
control the abundance of gene products in response to environmental and 
developmental changes. These biological processes can be modulated by post-
translational modifications including arginine methylation. Among the enzymes that 
catalyze the methylation, protein arginine methyltransferase 7 (PRMT7) is known 
to modify histones to repress gene expression. Jumonji domain-containing protein 
6 (JMJD6) is a putative arginine demethylase that potentially antagonize PRMT7. 
However, the biological significance of these enzymes is not well understood. This 
thesis summarizes the investigation of both PRMT7 and JMJD6 in cell culture 
models for adipocyte differentiation. The results suggest that PRMT7 is not 
required for the differentiation, whereas JMJD6 is necessary for the differentiation 
by promoting the expression of the lineage determining transcription factors 
peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-
binding proteins (C/EBPs). The underlying mechanisms by which JMJD6 regulate 
differentiation involve transcriptional and post-transcriptional control of gene 
expression. Unexpectedly, the adipogenic function of JMJD6 is independent of its 
enzymatic activity. Collectively, the present research reveals a novel role of 
JMJD6 in gene regulation during the differentiation of adipocytes.    
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CHAPTER I  
Introduction 
 
1.1 Protein arginine methylation  
 
Arginine has the most basic side-chain (pKa=12.48) among the twenty amino 
acids. At physiological pH, the guanidinium group of arginine side-chain is 
protonated and contains positive charges. This chemical property allows arginine 
to form multiple hydrogen bonds with electronegative molecules such as nucleic 
acids (1).  In mammalian cells, arginine can be methylated to form ω-NG-
monomethylarginine (MMA), ω- NG- NG-asymmetric dimethylarginine (ADMA), and 
ω- NG- N’G-symmetric dimethylarginine (SDMA) (2-4) (Figure I-1). The addition of 
methyl groups on arginine residues increases hydrophobicity and reduces 
hydrogen bonding. These effects could change protein structure and affect 
protein-protein or protein-nucleotide interactions (1).  
 
Arginine methylation is a common post-translational modification. Around 2 % 
of the arginine residues in rat liver nuclei and 1% of total arginine residues in 
human lung epithelial cells are methylated (5,6). Mass spectrometry (MS)-based 
proteomics either combined with immunopurification using methylation-specific 
antibodies or heavy methyl-stable isotope labeling by amino acids in cell culture 
(SILAC) method identified hundreds of arginine-methylated proteins in both human 
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methionine (AdoMet) to the guanidinium group of arginine side-chain and produce 
methylarginine and S-adenosylhomocysteine (AdoHcy). Nine PRMT genes have 
been identified in the mammalian genome (4). According to the methylation 
products, PRMTs are classified into three types (2): PRMT1, PRMT2, PRMT3, 
PRMT4, PRMT6 and PRMT8 are the type I PRMTs that produce ADMA (13-17). 
PRMT5 and PRMT9 are the type II PRMTs that deposit SDMA on substrates (18-
21). PRMT7 is assigned as a type III PRMT that only catalyzes MMA (22-25). 
However, some evidence suggests that PRMT7 has a type II activity (26-33).  
 
The PRMT family members share the characteristic catalytic domain 
composed of five conserved motifs named motif I, motif post I, motif II, motif III, 
and threonine-histidine-tryptophan (THW) loop (1,4,34) (Figure I-2). Motif I to motif 
III form a seven-stranded β sheet structure for AdoMet binding, whereas the THW 
loop helps substrate recognition by stabilizing the N-terminal helix of the enzyme. 
PRMT7 and PRMT9 differ from the other PRMTs, because they contain two 
putative catalytic domains. Both catalytic domains are essential for their enzymatic 
activities (21,22). Biochemical characterization showed that the N-terminal 
catalytic core of PRMT7 binds AdoMet, whereas the C-terminal catalytic core does 
not (22,35), suggesting that the C-terminal catalytic core only plays a structural 
role for the enzymatic function. 
 
In addition to the catalytic domain, PRMTs contain a signature motif called 
double E loop (1,4). The double E loop is following motif II and comprises of two 
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substrate, the ribosomal protein S2 (42). PRMT8 contains a myristoylation motif at 
the N-terminus, which is required for its targeting to the plasma membrane (17). 
The N-terminal region of PRMT9 contains three tetratricopeptide repeats (TPR), 
which could form an α-helix pair structure that mediates protein-protein 
interactions (43).  
1.3 Mouse models for PRMTs 
To understand the physiological functions of PRMTs in mammals, a number 
of genetically engineered mouse models have been generated (Table 1). The 
PRMT1 (44,45), PRMT4 (46,47), PRMT5 (48), and PRMT7 (33) deficient mice 
showed a range of developmental defects, whereas the PRMT2 (49), PRMT3 (50) 
and PRMT6 (51) deficient mice are viable without gross developmental 
abnormalities. A tamoxifen-inducible ER-PRMT6 transgenic mouse line is the only 
gain-of-function model that has been reported (52). 
 
PRMT1, PRMT4, PRMT5, and PRMT7 play significant and non-redundant 
roles in the cell growth, differentiation, or viability. Both PRMT1 hypomorphic and 
knockout embryos die shortly after implantation (44,45). PRMT5 knockout 
embryos die by E6.5 (48). The early embryonic lethality suggests that PRMT1 and 
PRMT5 are indispensable for proliferation and differentiation during early 
embryogenesis. PRMT4/CARM1 null mice die shortly after birth with smaller body 
size and defects in multiple tissues such as lung, T lymphocyte, adipose, muscle 
and chondrocyte (46,53-58). A mouse line with knock-in alleles of PRMT4 
catalytic-inactive mutation showed the same phenotypes as the PRMT4 null mice, 
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indicating that the methyltransferase activity of PRMT4 is essential for its role in 
vivo (47). The PRMT7 knockout mice have no obvious developmental defects at 
birth, however, most animals died within 5-10 days (33). Moreover, the B-cell 
specific PRMT7 knockout mice showed impaired B cell development in spleen and 
defective humoral immune responses (33). 
 
Table 1. Mouse models for PRMTs 
PRMT / allele Mutant phenotype  Refs 
PRMT1 / 
hypomorphic 
ES cells are viable. Embryos fail to develop 
beyond E8.5. 
 
(44) 
PRMT1 / 
conditional null 
Embryos do not survive to E7.5. MEFs show 
genomic instability and cell death.  
 
(45) 
PRMT2 / null  Mice are viable. MEFs show early S-phase 
entry, resistant to apoptosis, and increased NF-
κB activity. 
(49,59) 
PRMT3 / 
hypomorphic 
Mice are viable. Embryos are smaller than the 
wild-type embryos at E13.5 and E18.5.  
  
(50) 
PRMT4 / 
conditional null 
Neonatal lethality. Differentiation defects of T 
cells, adipocytes, chondrocytes, muscle cells, 
and pulmonary epithelial cells.   
(46,53-
58) 
PRMT4 / 
enzyme-dead 
knock-in 
The mutant mice phenocopy the PRMT4-null 
mice.  
 
(47) 
PRMT5 / null Blastocysts appear normal at E3.5, but 
embryos die by E6.5. No PRMT5-null ES cells 
could be obtained from blastocysts.  
 
(48) 
PRMT6 / 
conditional null 
Mice are viable. MEFs exhibited growth defects 
and cellular senescence.  
 
(51) 
PRMT6 /  
ER-PRMT6 
knock-in 
Mice have increased serum IL-6 levels. MEFs 
show enhanced NF-κB activity. 
    
(52) 
PRMT7 / 
conditional null 
A conditional null allele. Most mutant mice die 
within 5-10 days after birth. B cell differentiation 
(33) 
  
7 
in the bone marrow of B-cell specific knockout 
mice appears normal, but late B-development 
in spleen and humoral responses are impaired.  
 
Cells derived from different PRMT mouse models have been used for 
studying cellular and molecular functions of these enzymes. For example, the 
tamoxifen-inducible PRMT1fl/- ER-Cre MEF line was used to determine the 
function of PRMT1 in cell viability and genome stability (45). The PRMT2 knockout 
MEFs have an increased NF-κB activity and are more resistant to apoptosis than 
the wild-type cells (49). The PRMT4 knockout MEFs showed deficiencies in 
estrogen receptor, c-fos, PPARγ, and NF-κB-mediated transcription (46,55,60,61). 
Introduction of muscle lineage transcription factors into PRMT4 knockout MEFs 
failed to induce muscle genes and miRNA expression (56,62). PRMT6 knockout 
MEFs are prone to cellular senescence due to the activation of p53 pathway (51).  
 
Primary cells derived from PRMT mouse models were also used for 
substrates identification and antibody validation. For instance, a panel of MMA-, 
ADMA- and SDMA-specific antibodies was used to detect global arginine 
methylation in the PRMT1 knockout MEFs (63). This study not only showed that 
PRMT1 is the predominant enzyme responsible for ADMA modification, but also 
revealed an increase of MMA and SDMA levels when PRMT1 was depleted (63). 
The inducible PRMT5 knockout MEFs were used to quantify the SDMA levels that 
contributed by this enzyme (21). The results indicated that PRMT5 accounts for 
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the majority of SDMA in the MEFs, and the remaining type II activity might come 
from PRMT9 (21).   
 
1.4 Regulation of gene expression by PRMTs 
PRMTs participate in a wide range of mechanisms that control gene 
expression (1-4,64-68). PRMTs act as co-regulators for gene transcription and 
also modify histones and transcription regulators. In the subsequent step of gene 
expression, PRMTs methylate proteins involved in RNA processing and 
translation. These diverse functions of PRMTs in the regulation of gene expression 
are summarized below. 
1.4.1 Histone arginine methylation and chromatin regulation 
Histones are the basic proteins that help to package DNA into structure in 
the nucleus. They are well-identified substrates for PRMTs. Different PRMTs can 
methylate histones at distinct residues that associate with different transcriptional 
outcomes (Table 2).  
Table 2. Histone arginine methylation and the effects on transcription 
PRMT Methylated Histone and Transcriptional Effects Ref 
PRMT1 H4R3 (active) (69-71) 
PRMT2 H3R8 (unknown) (72) 
PRMT4 H3R17 (active), H3R26 (active) (73,74) 
PRMT5 H3R8 (active/repressive); H4R3 (repressive);  
H2AR3 (repressive) 
(48,56,75-
79) 
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PRMT6 H3R2 (repressive); H2AR29 (repressive); H3R42 
(active); H2AR3 (unknown); H4R3 (unknown) 
(66,80-85) 
PRMT7 H2AR3 (repressive), H4R3 (repressive),  
H3R2(active), H2BR29/31/33 (unknown) 
(24,27,30-
33) 
 
The mechanistic connections between histone methylation by PRMTs and 
gene transcription has been suggested. Histone arginine methylation can recruit 
other epigenetic modifiers to establish an active or repressive chromatin 
environment for subsequent transcription events. For instance, PRMT1-mediated 
asymmetrical dimethylation on histone H4R3 facilitates subsequent histone 
acetylation, because the methylated histone H4R3 is better substrate for 
CBP/p300 acetyltransferase (69-71). PRMT5-mediated H4R3 symmetrical 
dimethylation recruit DNA methyltransferase 3α (DNMT3A) to silence the human 
γ-globin gene via DNA methylation at the CpG sites around the promoter (86). 
Methylation on histone H4R3 by PRMT7 inhibits mixed-lineage leukemia 4 (MLL4) 
-mediated H3K4 methylation, and leads to gene repression (87). In addition, 
methylation of H3K4 is prevented by PRMT6-mediated H3R2 methylation, which is 
supported by structural and biochemical studies (80-83).  
 
Histone arginine methylation also regulates the chromatin binding of 
effector proteins that recognize the methylation state of arginine residues. For 
instance, the asymmetrical dimethylation on H4R3 and H3R17 is recognized by 
Tudor domain-containing protein 3 (TDRD3), a protein specifically binds 
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methylarginine peptides (88). Chromatin immunoprecipitation coupled with high-
throughput DNA sequencing (ChIP-seq) analysis showed that TDRD3 is generally 
associated with transcription start sits (TSSs) (88), suggesting that it is an effector 
protein for active methylarginine marks deposited by PRMT1 and PRMT4. 
Methylation on histones can also prevent the chromatin binding of protein factors. 
For example, PRMT1 and PRMT5-mediated H4R3 dimethylation inhibits the 
chromatin binding of signal recognition particle subunits SRP68 and SRP72 (89). 
Knockdown of SRP68 causes changes in its target gene expression, suggesting a 
function of SRP68 in transcription (89). Thus, histone arginine methylation is a part 
of the histone code (90) that regulates chromatin function and transcription.   
 
Several PRMTs collaborate with chromatin remodeling complexes to affect 
gene transcription. It is known that PRMT4, PRMT5 and PRMT7 are associated 
with the mammalian SWI/SNF complexes (31,76,91). The SWI/SNF complex is a 
multi-subunit protein complex that contains the ATPase Brahma (BRM) or 
Brahma-related gene 1(BRG1) for remodeling chromatin (92-95). PRMT4 and the 
SWI/SNF complex constitutes a nucleosomal methylation activator complex 
(NUMAC), where PRMT4 acquires the ability to methylate nucleosomal histones 
and also stimulates the catalytic activity of BRG1 (91). PRMT5 and PRMT7  
methylate nucleosomes more efficiently when they are associated with the 
SWI/SNF complex (68,76). Moreover, the loss of PRMTs can lead to a reduced 
binding of the SWI/SNF complex at the target gene promoters and gene 
expression (56,76-79), indicating that PRMTs not only fine-tunes the activity of the 
  
11 
chromatin remodeling complexes but also assist the loading of the remodeling 
enzymes to affect gene transcription. 
 
PRMT5 is also part of MBD2-NURD complexes (96,97), Ski co-repressor 
complexes (98) and Mediator complexes (99). When PRMT5 is associated with 
MBD2-NURD complex, it methylates histone H4R3 and MBD2 within the 
arginine/glycine-rich region at N-terminus (96). The methylation of MBD2 reduced 
its DNA binding affinity and the formation of MBD2-NURD complex at the target 
promoters (97).  PRMT5 was co-purified with histone deacetylates 3 (HDAC3) in 
the Ski complexes (98). The binding of PRMT5 and HDAC3 at the SMAD7 gene 
promoter correlates with the gene repression, suggesting that the collaboration of 
PRMT5 and HDAC3 establish a repressive chromatin environment for gene 
transcription. PRMT5 and its cofactor WDR77 (also called MEP50) are associated 
with the Mediator complexes to repress C/EBPβ target genes by deposition of 
methylated histone H4R3 and the subsequent DNA methylation (99). Therefore, it 
is clear that PRMT5 cooperates with the components of different chromatin 
complexes to regulate chromatin environment and transcription.   
 
1.4.2 Methylation of non-histone proteins in transcriptional controls 
PRMTs can modify signal transducers, transcription factors, co-regulators, 
and the transcription machinery to have effects on gene transcription (64). For 
instance, PRMT1 methylates estrogen receptor α (ERα) within the DNA binding 
domain upon estrogen stimulation in the MCF7 human breast cancer cell line 
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(100). This methylation facilitates the assembly of ERα with SRC and focal 
adhesion kinase (FAK) in the cytoplasm, leading to the activation of the AKT 
signaling pathway. PRMT1 also methylates FOXO1, a transcription factor involved 
in glucose metabolism and adipocyte differentiation (101). The methylation occurs 
in a consensus motif for AKT phosphorylation and prevents the phosphorylation by 
AKT. Consequently, FOXO1 is retained in the nucleus allowing gene expression. 
Other components of signal transduction pathways such as interferon receptor 
(102,103), JAK-STAT (104,105), TGFβ-SMAD (106), and Wnt (107) signaling 
pathways are also substrates for PRMT1. This evidence highlights the 
participation of PRMT1 in diverse biological processes by modifying signaling 
proteins and modulating the subsequent transcriptional responses. 
 
PRMT4 and PRMT5 also methylate transcription factors in response to 
external stimuli. PRMT4 methylates C/EBPβ, a MAP kinase signal-sensitive 
transcription factor regulating proliferation, differentiation, immunity and 
tumorigenesis (108). The methylation is abolished by MAP kinase-mediated 
phosphorylation at a conserved site within the regulatory domain of C/EBPβ. The 
substitution of arginine with lysine prevents C/EBPβ from interacting with SWI/SNF 
and Mediator complexes. The cells harboring this mutation failed to activate gene 
expression during myeloid and adipogenic differentiation, suggesting this 
methylation site is crucial for C/EBPβ to activate transcription. Similarly, the 
transcription activity of p53 can be modulated by arginine methylation in response 
to DNA damage (109). Ectopic expression of PRMT5 could lead to p53-dependent 
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cell cycle arrest, whereas depletion of PRMT5 triggers apoptosis. Thus, the protein 
level and methylation status of p53 could alter cellular response to stress.  
 
Transcription co-regulators are proteins that interact with transcription 
factors to either activate or repress gene transcription. The activity and assembly 
of co-regulator complexes can be modulated by arginine methylation. PRMT1 
methylates peroxisome proliferator-activated receptor γ co-activator 1-α (PGC-1α) 
(110) and nuclear receptor-interacting protein 1 (NRIP1, also known as RIP140) 
(111). PGC-1α and RIP140 are co-activators for the genes involved in energy 
metabolism. PRMT1-mediated methylation within a glutamate-and arginine-rich 
region at the C-terminus promotes PGC-1α’s co-activator activity. In contrast, 
PRMT1-mediated methylation triggers the dissociation of RIP140 from histone 
deacetylases and nuclear export of RIP140, suppressing its co-repressor activity.  
 
PRMT4 methylates CBP and p300 co-activators to promote their interaction 
with cAMP- response element-binding protein (CREB) and the steroid receptor co-
activators (SRCs) (112-114). In contrast, PRMT4 methylates the C-terminus of 
SRC-3, one of the SRC/p160 co-activator family members, leading to dissociation 
of PRMT4 and CBP from SRC-3 (115,116). Therefore, arginine methylation can be 
a regulatory signal for the assembly and disassembly of co-activator complexes. 
 
The components of the transcription machinery are also targets of PRMTs. 
PRMT4 methylates the residue of arginine 1810 within the C-terminal domain of 
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RNA polymerase II (117). Substitution of arginine to alanine at the methylation site 
results in altered expression of a variety of small nuclear RNAs and small 
nucleolar RNAs. Moreover, the methylation occurs on the hyperphosphorylated 
form of RNA polymerase II, and phosphorylation at serine 2 and serine 5 inhibits 
the methylation. This evidence suggests a cross-regulation between methylation 
and phosphorylation on the C-terminal domain of RNA polymerase that contributes 
to the transcription of selected genes. 
 
SPT5 is a transcriptional elongation factor that forms a heterodimer with 
SPT4 to positively or negatively regulate transcription elongation depending on the 
status of posttranslational modifications. The positive transcription elongation 
factor (P-TEFb) phosphorylates SPT5 into its stimulatory form (118,119). In 
contast, both PRMT1 and PRMT5 methylate SPT5, leading to a decreased 
association with RNA polymerase II and a repression of gene transcription (120).  
 
1.4.3 RNA processing  
RNA processing is tightly coupled with transcription and contains a series of 
steps including 5’-end capping, splicing, 3’-end cleavage and polyadenylation 
(121,122). Proteomic studies identified many RNA processing factors as PRMT 
substrates (7,8,10-12). However, in most cases, the consequence of the 
methylation remains to be elucidated (67).  
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Several PRMTs are known to affect RNA splicing. PRMT4 methylates the 
transcriptional elongation factor CA150 and splicing factors SAP49, SmB and U1C 
at the proline-, glycine- and methionine-rich (PGM) motif (123,124). The 
subsequent analysis showed that PRMT4 promotes exon skipping of an 
exogenous splicing reporter and the endogenous CD44 gene (124). Similarly, 
PRMT6 prevents exon inclusion of endogenous vascular endothelial growth factor 
(VEGF) and spleen tyrosine kinase (Syk) transcript in an enzymatic activity-
dependent manner (125), suggesting PRMT6 could also methylate splicing 
factors. 
 
The splicing function of PRMT5 and PRMT7 is linked to the methylation of 
Sm proteins (19,126-128). In the cytoplasm, the survival motor neuron (SMN) 
protein binds to the dimethylated Sm proteins to form the core protein structure for 
small ribonucleoprotein (snRNP) assembly (129). The mature snRNPs are 
imported into the nucleus and incorporated into spliceosome, the macromolecular 
machinery that carries out pre-mRNA splicing. Inhibition of SMN-Sm protein 
interaction leads to defective snRNP assembly and pre-mRNA splicing (129,130). 
 
PRMT9 is a newly characterized type II PRMT that specifically methylates 
splicing factors SAP145/SF3B2 and SAP49 (20). Transcriptome analysis identified 
changes in alternative splicing in the PRMT9 knockdown cells, indicating that 
PRMT9 is a non-histone arginine methyltransferase that regulates RNA splicing. 
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Heterogeneous nuclear ribonucleoproteins (hnRNPs) and the 
serine/arginine-rich (SR) proteins are also the targets of PRMTs (67). HnRNPs are 
a class of RNA binding proteins that are involved in pre-RNA splicing and mRNP 
packaging for nuclear export. The functional consequences of arginine methylation 
of hnRNPs are mostly unknown. However, in several cases, inhibition of arginine 
methylation changes intracellular localization and RNA binding ability of hnRNPs 
(131-135).  
 
The SR proteins are conserved, non-snRNP splicing proteins that are 
involved in multiple steps of RNA splicing. The SR proteins contain one or two 
RNA-recognition domains (RRM) and a C-terminal RS-rich domain. The RRM 
domain binds to RNA, whereas the RS-rich domain interacts with both protein and 
RNA. SF2/ASF protein is a splicing factor that has additional roles in RNA export, 
surveillance and translation. Substitution of arginine with alanine at three 
methylation sites increased cytoplasmic localization of SF2/ASF and caused 
defects in splicing and nonsense-mediated decay, a RNA surveillance pathway 
(136). Cells treated with adenosine dialdehyde (AdOx), a AdoHcy hydrolase 
inhibitor, led to the accumulation of SFRS9/SRp30c in nucleoli (137). Therefore, 
arginine methylation of SR proteins determines their intercellular localization and 
function in RNA processing.    
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1.4.4 Translation 
Arginine methylation occurs on proteins associated with the translation 
machinery (7,8,11,12). However, the consequences of the methylation are mostly 
uncharacterized. There are several reports that provide links between PRMTs and 
translation. PRMT3 and PRMT5 methylate different ribosomal subunits (42,138). 
Disruption of the PRMT3 gene in yeast resulted in the imbalance of the 40S:60S 
ribosomal subunit ratio (139). However, the reduction of PRMT3 levels in mouse 
cells had no effect (42). PRMT5 methylates ribosomal protein S10 (RPS10). 
Mutation at the methylation sites decreased its association with ribosomes and 
caused defective protein synthesis (138). Therefore, PRMTs can affect translation 
via the association with and methylation of the translation machinery.  
 
1.5 Reversal of arginine methylation 
1.5.1 Dynamic nature of arginine methylation 
The dynamic nature of arginine methylation has been demonstrated (65). For 
instance, estrogen stimulation results in a transient increase of ERα methylation in 
MCF7 cells (100). The level of methylation is at its peak within 5 minutes after 
estrogen treatment and then declines rapidly. Another study showed that estrogen 
stimulation leads to histone H3R17 methylation at the estrogen-responsive pS2 
promoter in a cyclic manner (140). Other study showed that the symmetric 
dimethylation on histone H4R3 at gene promoters was erased as the genes were 
derepressed (31). A rapid change in monomethylation on cellular proteins upon 
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transcription inhibition was uncovered in a proteomic study (9). These findings 
suggest that active arginine demethylation occur in nature, and that could be a 
consequence of the rapid turnover of the modified proteins or enzymatic reaction 
by uncharacterized demethylases.  
 
1.5.2 Putative arginine demethylase JMJD6 
JMJD6 is the only enzyme that has been shown to demethylate 
methylarginine on both histones (141,142) and non-histone proteins (143-148). It 
belongs to the family of iron- and 2-oxoglutarate-dependent oxygenases. The 
family members share a conserved catalytic domain composed of a double-
stranded β-helical fold. The catalytic domain was named JmjC domain because of 
the founding member jmj gene. The JmjC domain proteins target a broad range of 
substrates and participate in epigenetic regulation during development and in 
diseases (149). 
 
JMJD6 was reported to erase the methyl marks on histone H3R2 and H4R3 
(141). This was supported by western blot and MS-based analysis on bulk 
histones and histone peptides incubated with or without the enzyme. Additionally 
overexpression of the V5-tagged wild-type JMJD6 but not the iron-binding mutant 
reduced the overall methylation of H3R2 and H4R3 in HeLa cells. Other studies 
also suggested a demethylase function of JMJD6 for histone H4R3 (142,150). 
However, these findings were challenged by the studies showing that JMJD6 
instead catalyzes lysine hydroxylation on histones and splicing factors (151,152). 
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The conflicting history of JMJD6’s catalytic activity is also extensively reviewed 
(153). 
 
The importance of JMJD6 in development was suggested by the knockout 
mice studies. Three JMJD6 deficient mouse lines have been independently 
reported (154-156). JMJD6 deficient fetus showed severe differentiation defects in 
multiple tissues including eyes, heart, lung, kidney, intestine, and defective 
erythropoiesis and T lymphopoiesis, eventually leading to perinatal lethality. 
However, the mechanisms by which JMJD6 regulate tissue development are still 
not known. Moreover, the tissue specific roles of JMJD6 in both embryos and adult 
animals are not identified, largely due to the lack of tissue specific knockout or 
knockdown models. 
 
Recent evidences suggest that JMDJ6 is a versatile regulator for gene 
expression. JMJD6 modifies histones via arginine demethylation and lysine 
hydroxylation (141,142,152). It is tempting to hypothesize that JMJD6 antagonizes 
the action of PRMTs, especially PRMT1, PRMT5, PRMT6 and PRMT7, because 
these PRMTs methylate histone H3R2 and H4R3. Another study showed that 
lysine hydroxylation by JMJD6 has an inhibitory effect on acetylation and 
methylation on the same residues, and vice versa (152), suggesting a crosstalk 
between these modifications on histones. At the level of transcriptional regulation, 
JMJD6 controls RNA polymerase II elongation via its association with the active P-
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TEFb complexes and the dual demethylase activities of JMJD6 toward histone 
H4R3 and 7SK RNA at distal enhancers (142).  
 
JMJD6 also catalytically modifies transcription factors including p53 (157), 
estrogen receptor α (ERα) (144), PAX3 (148), and heat-shock protein of 70 kDa 
(HSP70) (145) to modulate their transcriptional activity or chromatin binding. 
Hydroxylation of p53 by JMJDJ6 represses p53 transcriptional activity by 
promoting the association of p53 with its negative regulator MDMZ (157). In 
response to estrogen treatment, JMJD6 demethylates ERα in MCF7 human breast 
cancer cells (144). JMJD6 also removes the methylation on PAX3, a transcription 
factor that controls transcription and differentiation in muscle and melanocyte 
lineages (148). The arginine methylation of PAX3 appears to be crucial for the 
loading of PAX3 on mitotic chromosomes. HSP70 is methylated by PRMT4 and 
demethylated by JMJD6, which regulates retinoid acid-induced gene expression 
(145). 
 
JMJD6 has an active role in RNA processing. It associates with multiple 
splicing regulatory proteins including U2 auxiliary factors (U2AFs) and SR proteins 
(151,158,159). Knockdown or over-expression of JMJD6 results in changes in 
alternative splicing (158,159). Notably, JMJD6 can regulate splicing of a 
constitutive splice reporter in a manner independent of catalytic activity (159), 
suggesting a scaffold function of JMJD6 in splicing. In addition to the association 
with RNA processing factors, JMJD6 is able to bind RNA in vitro (160) and in 
  
21 
cultured cells (159). Thus, JMJD6 might regulate RNA processing through direct 
binding with RNA and splicing proteins.  
 
1.5.3 Citrullination counteracts arginine methylation 
Protein citrullination is a posttranslational modification that converts peptidyl 
arginine to peptidyl citrulline. The reaction is also referred as deimination because 
it involves an exchange of an imine for a carbonyl group (1). The enzymes that 
catalyzes citrullination are named peptidylarginine deiminases (PADs) (161). The 
enzyme PAD4 was shown to convert monomethylarignine into citrulline, which 
removed the methyl group on guanidinium group (162). However, the subsequent 
studies determined that citrullination of methylarginine by PAD4 is inefficient (163). 
Moreover, other studies showed that methylation of the guanidinium group can 
even prevent it from citrullination (164,165). Therefore, citrullination likely serves 
as a mechanism that prevents arginine methylation rather than demethylation 
(166).  
 
1.6 Adipocyte differentiation 
1.6.1 Adipose tissues and functions 
Adipose tissue is composed of various types of cells including adipocytes, 
fibroblasts, endothelial cells, macrophages, and mesenchymal stem cells (167). 
White adipose tissue (WAT) and brown adipose tissue (BAT) are the two main 
types of adipose tissue, which are distinct in their morphology and function 
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(167,168). A typical WAT has light-colored appearance and contains mature 
adipocytes with large unilocular lipid droplets. It serves as triglyceride storage site 
and an endocrine organ for energy homeostasis.  In contrast, BAT has more 
capillaries than WAT. Brown adipocytes contain multilocular lipid droplets and a 
high content of mitochondria as compared to white adipocytes. The major role of 
BAT is to maintain body temperature and energy expenditure through 
thermogenesis.  
 
In addition to morphology and function, WAT and BAT have differences in 
body distribution and developmental pathways (167,168). In human, WAT is 
located mainly in abdominal and subcutaneous depots (167,169,170). Other sites 
such as retro-orbital, periarticular, intramuscular, pericardial depots and bone 
marrow, also contain WAT. BAT is found in the interscapular regions of infants, 
and cervical, supraclavicular and paravertebral sites in adults (167). The size and 
distribution of both WAT and BAT can change with age and diseases, and depot-
specific metabolic functions have also been studied (167). 
 
WAT and BAT originate from mesoderm, however, a divergence between 
white and brown adipocyte precursor along the developmental pathway was 
shown by the lineage-tracing studies in mice (171). BAT shares a common 
MYF5+PAX7+ precursor with muscle cells, whereas WAT precursor cells were 
found in neighboring blood vessels within the mature fat depots. Furthermore, the 
timing of WAT and BAT development is different. WAT begins to develop in late 
  
23 
gestation and undergoes a rapid expansion in postnatal stage in response to 
nutrient uptake. By contrast, BAT generally expands in utero (168).  
 
1.6.2 Adipocyte differentiation and cell culture models 
Adipocyte differentiation, also referred to as adipogenesis, is a 
developmental process during which multipotent stem cells convert into mature 
adipocyte. It takes place not only in developing embryos but also in adults. A 
human study showed a 10% annual turnover rate in adult human adipose tissues 
(172). Therefore, adipocyte differentiation is crucial for maintenance of adipose 
tissues throughout the body. In obese adults, adipose tissues undergo a 
characteristic expansion resulting from the enlargement of adipocyte size 
(hypertrophy) and the increase in adipocyte number (hyperplasia) (173). Adipose 
expansion has been examined in an Adipochaser mouse model by a high-fat diet 
challenge (174). The study determined that hypertrophy occurs in epididymal and 
subcutaneous adipose tissues at the early stages of high-fat diet challenge. A 
prolonged exposure to the high-fat diet causes expansion in gonadal adipose 
tissues but not in the subcutaneous fat depots. These results not only confirmed 
that adipogenesis occurs in response to nutrition overload, but also highlight the 
differences in adipogenic potential of various adipose depots. 
 
Adipocyte differentiation has been extensively studied using multiple cell 
models (175). Embryonic stem (ES) cells, mouse embryonic fibroblasts (MEFs), 
bone marrow and fat stromal derived cells are the major sources for the primary 
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cells. Moreover, MEFs or stromal cells can be immortalized by either 3T3 protocol 
or introduction of SV40 large T-antigen to allow sustained manipulation. 
Immortalized cell lines such as 3T3-L1, 3T3-F422A, C3H10T1/2 and OP9 
differentiate spontaneously upon hormonal treatment (176-179). In contrast, the 
non-adipogenic cell lines such as NIH3T3 and other immortalized MEFs can be 
differentiated into adipocytes by introduction of adipogenic transcription factors 
such as peroxisome proliferator-activated receptor γ (PPARγ) and 
CCAAT/Enhancer binding protein α and β (C/EBPα and C/EBPβ) (180-182). 
 
1.6.3 Transcriptional regulation of adipocyte differentiation 
The transcriptional network for adipocyte differentiation is centered on the 
nuclear receptor PPARγ (175,183), which is a transcription factor both necessary 
and sufficient for adipogenesis (181,184,185). The transcription of Pparγ gene 
gives rise to two protein isoforms, PPARγ1 and PPARγ2, through alternative 
splicing and promoter usage (186). Both isoforms promote adipogenesis in the 
PPARγ-null MEFs, despite the fact that PPARγ2 is more efficient (187). PPARγ is 
also required for maintenance of cellular phenotype and survival of mature 
adipocytes (188,189). Although many other adipogenic factors had been identified, 
no factor can function efficiently in the absence of PPARγ. Therefore, PPARγ is 
considered the master regulator of adipogenesis. 
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C/EBP family transcription factors have crucial roles in the adipogenic 
differentiation by either facilitating transcriptional activation of PPARγ or 
collaborating with PPARγ to activate downstream targets. C/EBPβ and C/EBPδ are 
induced early during differentiation by cAMP agonist 3-isoburyl-1-methlxanthine 
(IBMX) and glucocorticoid agonist dexamethasome (190). These two early pro-
adipogenic transcription factors activate the expression PPARγ and C/EBPα 
through a direct binding at the promoters and enhancers (191,192). A double 
knockout mouse line showed a significant reduction in adipose tissues, whereas 
the lack of either C/EBPβ or C/EBPδ only had a partial reduction in adipose 
formation (193), supporting the idea that these two transcription factors cooperate 
to initiate adipocyte differentiation both in vitro and in vivo. Different from C/EBPβ 
and C/EBPδ, C/EBPα expression is relatively late during adipogenesis (190). 
C/EBPα collaborates with PPARγ to promote adipocyte differentiation and 
phenotype maintenance (194,195). It is also required for the insulin sensitivity in 
adipocytes (194).  
 
Many other pro-adipogenic and anti-adipogenic transcriptional factors and 
cofactors have been characterized over the past two decades. These studies have 
also been extensively reviewed (168,175,183,196-198). Krupprl-like factors (KLF4, 
KLF5, KLF6 and KLF15), E2F family transcription factors (E2F1-3), early growth 
response-2 (EGR2, also known as Krox20), cAMP response element binding 
protein (CREB), glucocorticoid receptor (GR), signal transducer and activator of 
transcription 5A/B (STAT5A/B), retinoid X receptor (RXR) and sterol regulatory 
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element-binding protein 1c (SREBP-1c) are pro-adipogenic factors that stimulate 
PPARγ and C/EBPα expression. A series of negative regulators including E2F4, 
GATA2, GATA3, KLF2, KLF3, FOXO1 and β-catenin/TCF4 suppress PPARγ or 
C/EBPα expression.  The co-regulators such as SWI/SNF chromatin remodelers, 
the Mediator complex, CBP/p300 acetyltransferases and MLL3/MLL4 
methyltransferases facilitate chromatin remodeling and enhancer establishment for 
the expression of PPARγ and other adipogenic genes. In contrast, H3K9 
methyltransferase G9a directly represses PPARγ expression. The co-repressor 
complexes NCoR and SMRT, and the Sirt1 NAD-dependent protein deacetylase 
are involved in the repression of PPARγ target genes.  
 
Global transcription and epigenomic alterations during adipocyte 
differentiation were determined by a number of studies using genome-wide 
profiling approaches for RNA levels, histone modifications, and chromatin binding 
of transcription factors and cofactors in the differentiating adipocytes, particularly 
in 3T3-L1 adipocytes (192,195,199-205). The genome-wide distribution of various 
histone modifications such as H3K4me1/2/3, H3K27Ac, H3K27me3, H3K36me3 
and H3K9Ac has been mapped in differentiating 3T3-L1 cells (199,200,202). 
These studies help to define the activity of gene promoters and enhancers. 
Changes in chromatin structure were determined by DNase site analysis in 
combination with high throughput DNA sequencing (DHS) (192). The results 
correlate with changes in gene expression and the cooperative binding of multiple 
transcription factors and cofactors at the specific genomic loci 
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(192,195,199,200,202-205). These findings greatly advance our knowledge on the 
mechanisms by which the adipogenic signals integrate at specific chromatin sites 
for initiation of the transcription program during differentiation. 
 
1.6.4 PRMT in regulation of adipocyte differentiation 
Among the nine members of PRMT family, PRMT4 and PRMT5 affect 
adipocyte differentiation (55,79). The PRMT4 knockout embryos developed less 
BAT at E18.5 as compared to the wild-type embryos (55). The PRMT4 knockout 
MEFs failed to differentiate into adipocytes. Knockdown of PRMT4 in 3T3-L1 
preadipocytes also impaired their differentiation. The molecular analyses showed 
that PRMT4 co-activated PPARγ and was recruited to an endogenous adipocyte 
specific gene ap2/FABP4 (55), indicating that PRMT4 acts as a co-activator to 
promote PPARγ target gene expression. However, it is still unclear whether 
PRMT4 affects the expression of PPARγ and C/EBPs genes in the early stage of 
differentiation and in vivo.  
 
PRMT5 is directly involved in both the activation of PPARγ and PPARγ 
target genes (79). Knocking down PRMT5 decreased the adipogenic potential of 
3T3-L1 and C3H10T1/2 cells. In contrast, ectopic expression of PRMT5 promotes 
differentiation in these two cell lines. Introduction of either PPARγ or C/EBPα into 
the non-adipogenic NIH3T3 fibroblasts promoted adipogenic differentiation upon 
hormonal induction. However, when PRMT5 was depleted in the NIH3T3 
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fibroblasts, the cells failed to differentiate. More interestingly, the loss of PRMT5 
prevented the binding of BRG1 at the PPARγ or C/EBPα target promoters and 
enhancers, suggesting that PRMT5 might assist the loading of BRG1-based 
SWI/SNF complexes at promoters and enhancers to facilitate gene transcription 
(79).  
 
Due to the lack of mouse models, the in vivo adipocyte function of PRMT5 
is unknown.  Interestingly, deletion of Copr5, a binding partner of PRMT5, reduced 
the number of adipocytes in the retroperitoneal WAT in 8 and 16 week-old mice 
(206). The adipogenic differentiation of embryoid bodies and primary MEFs from 
the knockout mice was significantly delayed. Subsequent studies indicated that 
COPR5 and PRMT5 repressed the expression of Dlk-1, a negative regulator of 
adipogenesis (206). Thus, PRMT5 functions as both a co-activator and a co-
repressor in a gene-specific manner during adipogenesis.  
 
1.7 Outstanding questions and research scope 
Arginine methylation is a post-translational modification crucial for many 
cellular and developmental processes. Although the functions and targets of 
PRMTs had been extensively studied, the connection between the molecular 
function of each PRMT and the biological events is not fully established. Moreover, 
it was proposed that JMJD6 is an arginine demethylase that antagonizes certain 
PRMTs. However, the enzymatic activity of JMJD6 is still contradictory. The 
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counteracting actions between PRMTs and JMJD6 should be carefully examined 
in a given biological process.   
 
In this thesis, I describe my investigation of PRMT7 (Chapter II) and JMJD6 
(Chapter III) in models for adipocyte differentiation. PRMT7 and JMJD6 are two 
distinct enzymes that potentially antagonize each other in arginine methylation and 
gene expression. By using the well-characterized differentiation models, I wished 
to determine whether and how these enzymes regulate gene expression and 
cellular differentiation. My work showed that PRMT7 is dispensable, whereas 
JMJD6 is necessary for adipocyte differentiation. The adipogenic function of 
JMJD6 is independent of its enzymatic activity. The characterization of the 
underlying mechanisms by which JMJD6 regulates gene expression during 
differentiation is also presented. 
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CHAPTER II  
Characterization of PRMT7 in Adipocyte Differentiation  
2.1 Abstract 
Protein arginine methyltransferase 7 (PRMT7) is categorized as a type II 
and type III enzyme that produces symmetric dimethylated arginine and 
monomethylated arginine, respectively. However, the biological role of PRMT7 is 
not well characterized. We previously showed that PRMT5, a type II PRMT that 
associates with BRG1-based SWI/SNF chromatin remodeling complex, is required 
for adipocyte differentiation. Since PRMT7 also associates with BRG1-based 
SWI/SNF complex and modifies core histones, we hypothesized that PRMT7 
might play a role in transcriptional regulation of adipogenesis. In the present study, 
we determined that the expression of PRMT7 did not change throughout 
adipogenic differentiation of C3H10T1/2 mesenchymal cells. Knockdown or over-
expression of PRMT7 had no effect on lipid accumulation or adipogenic gene 
expression in differentiating C3H10T1/2 cells or in C/EBPα-reprogrammed NIH3T3 
fibroblasts. Based on these results, we conclude that PRMT7, unlike PRMT5, is 
dispensable for adipogenic differentiation in tissue culture models. 
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2.2 Materials & Methods 
2.2.1 Cell line 
Mouse C3H10T1/2 and NIH3T3 cells were obtained from the ATCC. 
C3H10T1/2 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) high glucose (Invitrogen) supplemented with 10% fetal calf serum (FCS) 
(Sigma) and 100U/ml of penicillin/streptomycin (Invitrogen). NIH3T3 cells were 
maintained in DMEM high glucose with 10% calf serum (Sigma). 293T and 
BOSC23 cells were obtained from Dr. S.N. Jones (UMass Medical School) and Dr. 
R.E.Kingston (Massachusetts General Hospital), respectively, and were grown in 
the same medium as C3H10T1/2 cells. For adipogenic differentiation, two-day 
postconfluent cells were differentiated with DMEM medium containing 10% FCS, 
10µg/ml insulin, 0.5mM 3-isobutyl-1-methyxanthine, 1µM dexamethasone, and 
10µM troglitazone (Sigma). After 48 hours incubation, media on the differentiating 
cells was replaced with media containing 5µg/ml insulin. Subsequently, the media 
was changed every other day until harvest. To evaluate cell proliferation, 1x105 
cells were seeded in 6-well plates (Corning Inc.), and the number of viable cells 
was counted under a microscope (CK2, Olympus) each day from day 1 to day 4 
with a hemocytometer (Hausser Scientific). 
 
2.2.2 Plasmid DNA construction 
pENTR/pTER+ vector and pLentiX2 Dest vector were gifts from Dr. Eric 
Campeau (UMass Medical School). The preparation of lentiviral small hairpin RNA 
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(shRNA) constructs was done as previously described (31,188). Briefly, 
shPRMT7-1, shPRMT7-2 and scrambled control oligonucleotides were cloned into 
a pENTR/pTER+ vector. These constructs were individually incubated with the 
pLentiX2 DEST vector and LR clonase II enzyme mix (Invitrogen) to generate 
pLentiX2 DEST/ shPRMT7-1, pLentiX2 DEST/shPRMT7-2 and pLentiX2 
DEST/shCtrl constructs. These lentiviral constructs were amplified in Stbl3 
competent cells (Invitrogen) for generating lentiviruses. The pBABE puromycin 
empty vector (pBABE vector), FLAG-tagged PRMT7 construct (pBABE PRMT7) 
and pBABE CEBPα construct were previously described (31,189) and were 
individually amplified in TOP10 competent cells (Invitrogen) for generating 
retroviral DNA as previously described (31,189). 
 
2.2.3 Virus preparation and transduction 
The preparation of viruses was performed as previously described 
(188,190). Briefly, for lentiviruses, the packaging vectors pLP1, pLP2, pVSVG 
(Invitrogen) and pLentiX2 DEST/shRNA constructs were co-transfected into 293T 
cells with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s 
instructions. BOSC23 cells were used for pBABE-based retrovirus production. 
After 48 hours incubation, the supernatant was harvested and filtered through 
0.45µm syringe filter (Millipore). For viral infection, 1ml of the filtered supernatant 
and 4µg/ml of polybrene (Sigma) were used to infect one million cells. After 48 
hours incubation, virus infected cells were selected in 2.5µg/ml puromycin 
(Invitrogen). 
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2.2.4 Protein expression analysis 
Cells were washed twice with cold PBS and were harvested in RIPA buffer 
(50mM Tris-HCl pH7.4, 150mM NaCl, 1mM EDTA, 1% Nonidet P-40 and 0.25% 
sodium deoxycholate) supplemented with protease inhibitor cocktail (Roche). The 
samples were sonicated at high intensity setting for 3 minutes with 30sec on/off 
cycle in a Bioruptor (UCD-200, Diagenode). After quantifying the protein 
concentration by means of a Bio-Rad protein assay, the protein samples were 
then mixed with 4X SDS loading buffer (240mM Tris-HCl pH6.8, 8% SDS, 40% 
glycerol, 0.01% bromophenol blue and 10% β-mercaptoethanol) and boiled at 
95°C for 10min. 30µg protein samples were separated on 10% SDSPAGE and 
transferred onto PVDF membrane (Bio-Rad). The blots were blocked overnight in 
3% non-fat milk (Essential Everyday). The next day, proteins were detected using 
specific antibodies (1:1000 dilution) and HRP-conjugated secondary antibodies 
(1:2000 dilution). The rabbit polyclonal antibodies against human PRMT7 (sc-
98882) and rat C/EBPα (sc-61) were purchased from Santa Cruz Biotechnology. 
The mouse monoclonal antibody against mouse PPARγ (sc-7273) and the goat 
polyclonal antibody against human Prmt5 (sc-22132) were also purchased from 
Santa Cruz Biotechnology. Rabbit polyclonal anti-PI3K (ABS233) antibody was 
from Millipore. The secondary antibodies (NA9340 and NA9310) were purchased 
from GE Healthcare Life Sciences. The blots were developed on X-ray films with 
ECL Western Blotting Detection Reagents (GE Healthcare Life Sciences). The 
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signal intensity was quantified by ImageJ. 
 
2.2.5 Gene expression analysis 
Total RNA was isolated from samples using TRIzol reagent (Invitrogen) 
according to the manufacturer’s instructions. cDNA was prepared from 1µg of total 
RNA by Superscript III reverse transcriptase kit (Invitrogen). Quantitative PCR was 
performed on StepOne Plus real-time PCR machine with Fast SYBR Green 
Master mix (Applied Biosystems). The specific primers for gene expression 
analysis were listed in Table A1. Relative expression levels were determined by 
the comparative Ct method (207). 
 
2.2.6 Oil Red O staining 
Differentiating cells were washed once with PBS and fixed in 10% 
phosphate-buffered formalin (Fisher Scientific) overnight. The next day, the fixed 
cells were washed with 60% isopropanol and air dried completely. The cells were 
then stained with 60% Oil Red O (AMRESCO) for 10 minutes and washed 
repeatedly with tap water to remove excess stain. To quantify staining, Oil Red O 
was extracted from the cells with 100% isopropanol, and the optical density was 
measured at 500nm (OD500). 
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2.3 Results 
2.3.1 Expression of PRMT7 remains constant during differentiation 
The C3H10T1/2 cell line was established from C3H mouse embryos and 
has served as a faithful cell culture model for mesenchymal lineage differentiation 
(208-210). C3H10T1/2 cells can be differentiated into mature adipocytes by 
treating the confluent cells with a cocktail that contains insulin, dexamethasone, 3-
isobutyl-1-methyxanthine (IBMX) and PPARγ ligands such as Troglitazone (211). 
Using this model, we first examined PRMT7 protein levels during adipogenic 
differentiation by Western blot analysis. We found that PRMT7 protein levels are 
relatively constant from the onset of differentiation (day 0) through the day 6 post-
differentiation (Figure II-1A and Figure II-1B). We concluded that PRMT7 protein 
levels were not altered in differentiating C3H10T1/2 cells. 
       
Figure II-1. The expression of PRMT7 remains constant in the 
differentiating C3H10T1/2 cells. 
(A) Western blot analysis of protein extracts from day 0 to day6 post-
differentiated C3H10T1/2 cells. Duplicate blots were probed with anti-
PRMT7 antibody and with anti-PI3K antibody as a loading control. (B) The 
quantification of (A) by Image J. The levels of PRMT7 were normalized to 
PI3K loading control and presented as the relative expression levels to the 
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day 0 sample (day 0 = 1). The data represent the average of two 
independent experiments (n=2).  
 
2.3.2 PRMT7 has no effect on cell proliferation  
To study the function of PRMT7, we used viral vectors to knock down or 
over-express PRMT7 in C3H10T1/2 cells. Two lentiviral constructs (pLentiX2 
DEST/shPRMT7-1 and pLentiX2 DEST/shPRMT7-2) that encode shRNAs against 
PRMT7 mRNA were used for knocking down endogenous PRMT7 in proliferating 
C3H10T1/2 cells. A pBABE retroviral construct (pBABE-PRMT7) encoding FLAG-
tagged PRMT7 was used to over-express PRMT7. The virus-infected cells were 
selected with puromycin and the levels of PRMT7 in the selected cells were 
examined by Western blot analysis (Figure II-2A). Endogenous PRMT7 levels 
were reduced 10-fold or more in the knockdown cells compared to the scrambled 
shRNA control cells (Figure II-2B). PRMT7 levels were increased more than 5-fold 
in the FLAG-tagged PRMT7 over-expression cells compared to the pBABE empty 
vector control (Figure II-2B). Since PRMT5 is the major type II arginine 
methyltransferase and is also associated with SWI/SNF complexes (76), we 
examined PRMT5 protein levels in our samples. We observed no changes in 
PRMT5 levels in PRMT7 knockdown and overexpression C3H10T1/2 cells (Figure 
II-2A). 
 
Both PRMT7 and PRMT5 exhibit type II arginine methyltransferase activity. 
However, unlike PRMT5, PRMT7 has no effect on cell proliferation in NIH3T3 
fibroblasts (31). We measured the cell proliferation rate of PRMT7 knockdown and 
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over-expression C3H10T1/2 cells, and found that neither the reduction of PRMT7 
nor the over-expression of PRMT7 affected the proliferation of C3H10T1/2 cells 
(Figure II-3). This result is consistent with the results from the previous study on 
NIH3T3 fibroblasts (31). 
                  
Figure II-2. Knockdown and over-expression of PRMT7 in C3H10T1/2 
cells. 
(A) A representative Western blot analysis from proliferating C3H10T1/2 
cells with PRMT7 knockdown and over-expression. Endogenous PRMT7 
was specifically depleted by two different lentiviral shRNA constructs 
(shPrmt7-1 and shPrmt7-2). The scrambled shRNA lentiviral construct 
(shCtrl) was used as a control. The pBABE retroviral construct encoding 
FLAG-tagged PRMT7 (pBABE-PRMT7) was used to ectopically express 
PRMT7, and the pBABE empty vector (pBABE vector) was used as a 
control. The blot was probed with anti-PRMT7 and anti-PRMT5 antibodies, 
and re-probed with anti-PI3K antibody as a loading control. (B) The 
quantification of PRMT7 in (A) by ImageJ. The levels of PRMT7 were 
normalized to the PI3K loading control and are presented as expression 
levels relative to the scrambled shRNA control or pBABE empty vector 
control. The data represent the average of two independent experiments 
(n=2). 
  
  
38 
                                      
Figure II-3. PRMT7 has no effect on cell proliferation. 
The growth rates of control (shCtrl and pBABE vector), PRMT7 knockdown 
(shPRMT7-1 and shPRMT7-2) and PRMT7 over-expression (pBABE 
PRMT7) C3H10T1/2 cells were measured by seeding 1×105 cells in 6-well 
plates, and the viable cells were counted each day for 4 days after seeding. 
The data represent the average of two independent experiments (n=2) 
counted in duplicate. Error bars show the standard deviation.  
 
2.2.3 PRMT7 is not required for adipogenic differentiation  
To determine whether PRMT7 affects adipogenesis, the PRMT7 
knockdown and over-expression C3H10T1/2 cells were grown to confluence and 
treated with the differentiation cocktail. At day 6 post-differentiation, the 
accumulation of intracellular neutral lipids was measured by Oil Red O staining. 
The Oil Red O staining showed similar levels of lipid accumulation in PRMT7 
knockdown as well as PRMT7 overexpression cells as compared to the control 
cells. (Figure II-4A and Figure II-4B). This result suggests that the changes in 
PRMT7 levels did not affect lipid accumulation in differentiating C3H10T1/2 cells. 
 
PPARγ and C/EBPα are the key transcription factors for adipogenic 
differentiation and for the maintenance of the adipocyte phenotype 
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(180,181,195,205). We examined the protein levels of PPARγ and C/EBPα in day 
6 post-differentiation cells by Western blot analysis and found no significant 
difference in either PRMT7 knockdown or PRMT7 over-expression cells compared 
to the corresponding controls (Figure II-4C). In addition, to rule out the possibility 
that PRMT7 functions as a cofactor of PPARγ and C/EBPα, we measured the 
mRNA expression levels of PPARγ and C/EBPα target genes in day 6 post-
differentiation samples by real-time quantitative PCR (Figure II-4D). We found that 
PRMT7 has no significant impact on fatty acid synthase (Fasn), adiponectin 
(AdipoQ), and fatty acid binding protein 4 (Fabp4) gene expression in the 
differentiating cells. These results suggest that PRMT7 is dispensable for 
adipogenic gene expression. 
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Figure II-4. PRMT7 has no effect on the adipogenic differentiation of 
C3H10T1/2 cells.  
(A) Representative Oil-Red O staining images of day 6 post-differentiated 
C3H10T1/2 cells in which Prmt7 was either knocked down (shPrmt7-1 and 
shPrmt7-2) or over-expressed (pBABE PRMT7). The Prmt7 knockdown and 
over-expression C3H10T1/2 cells were grown to confluence and 
differentiated 48 h later. At day 6 post-differentiation, the cells were fixed 
with 10% formalin and stained with Oil-Red O. (B) The quantification of (A). 
The Oil-Red O stain was extracted with 100% isopropanol and the optical 
density at 500nm (OD500) was determined. The data represent the average 
of two independent experiments (n=2) assayed in duplicate.  Error bars 
show standard deviation. (C) A representative Western blot analysis of 
endogenous Prmt7, PPARγ and C/EBPα expression in day 6 post-
differentiated C3H10T1/2 cells. The levels of PI3K are presented as a 
loading control. (D) Gene expression analysis on day 6 post-differentiated 
C3H10T1/2 cells. The mRNA levels of fatty acid synthase (Fasn), 
adiponectin (AdipoQ) and fatty acid binding protein 4 (Fabp4) were 
measured by RT-qPCR. The individual mRNA levels were normalized to 5S 
rRNA. The normalized expression levels of the control cells were set as 1. 
The data are presented as the average of relative expression levels from 
two independent experiments (n=2) assayed in duplicate.  Error bars show 
standard deviation. 
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Previous studies had shown that ectopic expression of PPARγ or C/EBPα 
alone in non-adipogenic NIH3T3 cell line reprograms NIH3T3 fibroblasts into 
adipocyte-like cells (180,181). To test if PRMT7 is required for the reprogramming 
of NIH3T3 fibroblasts, we first knocked down and over-expressed PRMT7 in 
NIH3T3 fibroblasts by using the same viral constructs that we used in C3H10T1/2 
cells, and confirmed the knockdown and over-expression of PRMT7 by Western 
blot analysis (Figure II-5A). These cells were further infected with the retroviruses 
encoding C/EBPα at 70 % confluence. After the cells reached confluence, the 
differentiation cocktail was added to stimulate adipogenic differentiation. At day 6 
post-differentiation, the accumulated lipid was evaluated by Oil Red O staining 
(Figure II-5B). We found that neither knockdown nor over-expression of PRMT7 
caused a significant difference in Oil Red O staining in C/EBPα-reprogrammed 
NIH3T3 fibroblasts, which is consistent with the results in C3H10T1/2 cells. 
                      
        
 
Figure II-5. PRMT7 does not affect C/EBPα-mediated reprogramming 
of NIH3T3 fibroblasts. 
(A) Western blot analysis on PRMT7 knockdown and over-expression 
NIH3T3 fibroblasts. Endogenous PRMT7 was specifically depleted by the 
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lentiviral shRNA constructs (shPRMT7-1 and shPRMT7-2). The scrambled 
shRNA lentiviral construct (shCtrl) was used as a control. The pBABE 
retroviral construct encoding FLAG-tagged PRMT7 (pBABE PRMT7) was 
used to ectopically express PRMT7 and the pBABE empty vector was used 
as a control. The blot was probed with anti-Prmt7 antibody, and the PI3K 
levels are presented as a loading control. (B) Oil-Red O staining images of 
C/EBPα-reprogrammed NIH3T3 fibroblasts at day6 post-differentiation. 
Prmt7 knockdown and over-expression NIH3T3 fibroblasts were infected 
with retroviruses encoding C/EBPα at 70% confluence. Two day post-
confluent cells were differentiated. At day 6 post-differentiation, the cells 
were fixed with 10% formalin and stained with Oil-Red O. 
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2.4 Discussion 
Changes in gene expression during cell differentiation require alterations in 
higher-order chromatin organization as well as in local chromatin structure. Cells 
possess histone modifying enzymes and ATP-dependent chromatin remodeling 
enzymes to facilitate chromatin changes. The interplay between these two families 
of enzymes has been shown to be crucial for both transcription activation and 
repression (76,92,212). PRMT7 was identified as a histone arginine methylating 
enzyme (23,25,26) and was shown to associate with BRG1-based SWI/SNF ATP-
dependent chromatin remodeling complex (31). These findings led us to 
investigate the possible roles of PRMT7 in adipogenic differentiation, which is a 
process that requires the function of BRG1-based SWI/SNF complex (213). Our 
data clearly showed that PRMT7 levels were significantly changed in the 
knockdown or overexpression cells, but manipulation of PRMT7 levels did not 
cause a differentiation deficiency. It is established that BRG1-based SWI/SNF 
complex is recruited to the adipogenic promoters upon differentiation. However, 
whether PRMT7 associates with BRG1-based SWI/SNF complex at adipogenic 
promoters is still unknown. Since PRMT7 has no effect on adipogenic gene 
expression, we expect that PRMT7 is not recruited to adipogenic promoters. 
Alternatively, even if there is binding, the function of PRMT7 is dispensable at 
these loci. 
 
Functional redundancy within the PRMT family has not been characterized. 
PRMT7 was classified as a type II and a type III arginine methyltransferase by 
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characterization of its in vitro catalytic activity (22,23,25,26). Whether other 
PRMTs functionally compensate for PRMT7 is still unknown. The predominant 
type II arginine methyltransferase PRMT5 catalyzes the formation of MMA and 
SDMA in a nonprocessive fashion (18,214). Type I arginine methyltransferases 
also produce MMA (13,16,215). It is possible that PRMT5 or type I PRMTs 
partially or fully compensate for the loss of PRMT7 in the cells. Our data showed 
that PRMT7 knockdown or over-expression has no effect on PRMT5 protein levels 
in C3H10T1/2 cells. This observation is consistent with the results from the 
previous study in HeLa cells (128). However, we still cannot rule out the possibility 
that PRMT5 compensates for PRMT7 enzyme activity, even though PRMT5 
protein levels remain constant. Further investigation is needed to address the 
possible crosstalk between PRMT5 and PRMT7 in chromatin regulation. 
 
Whether changes in PRMT7 levels cause any developmental deficiencies in 
vivo remains to be elucidated. Several studies using cell lines or tissues have 
revealed regulatory roles for PRMT7 in tissue-specific gene expression. For 
example, PRMT7 negatively regulates neuronal differentiation of a human 
embryonal carcinoma cell line by repressing the expression of differentiation-
specific genes (87). In mouse germ cells, PRMT7 was recruited to the imprinting 
control region through physical interaction with CTCFL, a testis-specific nuclear 
protein, and repressed imprinted gene expression (27). Furthermore, mouse 
embryonic stem cells and germ cells have relative high levels of PRMT7 compared 
with mouse embryonic fibroblasts (216,217). This evidence suggest that PRMT7 
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might have important functions in the maintenance of stem cell pluripotency and 
that the down-regulation of PRMT7 might be required for early cell fate 
determination. Taken together, these data suggest that PRMT7 might have a role 
during early development. 
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CHAPTER III  
Roles of JMJD6 in Adipocyte Differentiation 
 
3.1 Abstract  
JMJD6 is a nuclear protein involved in histone modification, transcription, 
and RNA processing. Although JMJD6 is crucial for tissue development, the link 
between its molecular functions and its roles in any given differentiation process is 
unknown. We report that JMJD6 is required for adipogenic gene expression and 
differentiation in a manner independent of Jumonji C domain catalytic activity. 
JMJD6 knockdown led to a reduction of C/EBPβ and C/EBPδ protein expression 
without affecting mRNA levels in the early phase of differentiation. However, 
ectopic expression of C/EBPβ and C/EBPδ did not rescue differentiation. Further 
analysis demonstrated that JMJD6 was associated with the Pparγ2 and Cebpα loci 
and putative enhancers. JMJD6 was previously found associated with 
bromodomain and extra-terminal domain (BET) proteins, which can be targeted by 
the bromodomain inhibitor JQ1. JQ1 treatment prevented chromatin binding of 
JMJD6, Pparγ2 and Cebpα expression, and adipogenic differentiation, yet had no 
effect on C/EBPβ and C/EBPδ expression or chromatin binding. These results 
indicate dual roles for JMJD6 in promoting adipogenic gene expression program 
by post-transcriptional regulation of C/EBPβ and C/EBPδ and direct transcriptional 
activation of Pparγ2 and Cebpα during adipocyte differentiation.   
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3.2 Materials and Methods 
3.2.1 Cell culture  
Mouse C3H10T1/2, 293T, and BOSC23 cells were maintained in growth 
media consisting of DMEM high glucose medium (Invitrogen), 10% fetal calf serum 
(FCS, Sigma) and 100 U/ml penicillin/streptomycin (Invitrogen). For adipogenic 
induction, confluent cells were cultured in DMEM high glucose medium 
supplemented with 10% FCS, 10 µg/ml insulin, 0.5 mM IBMX, 1 µM 
dexamethasome, and 5 µM Troglitazone (all reagents from Sigma) for 48 h. After 
induction, the differentiating cells were maintained in DMEM high glucose medium 
supplemented with 10% FCS and 5 µg/ml insulin. Media was changed every other 
day until harvest.  
 
3.2.2 Plasmid DNA construction    
pENTR/pTER+ vector and pLentiX2 DEST vector were gifts from Dr. Eric 
Campeau. The preparation of small hairpin RNA (shRNA) lentiviral constructs was 
performed as previously described (218). Briefly, JMJD6 shRNAs, GFP shRNA 
and scrambled sequence shRNA oligonucleotides were individually cloned into 
pENTR/pTER+ vector. The pENTR/pTER+ shRNA constructs were subsequently 
incubated with LR clonase II enzyme mix (Invitrogen) and pLentiX2 DEST vector 
containing a puromycin resistance gene to generate pLentiX2 DEST/shJmjd6, 
pLentiX2 DEST/shGFP, and pLentiX2 DEST/shCtrl constructs. The sequences of 
shRNA oligonucleotides are listed in Table A1. To generate the constructs for 
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JMJD6 and HIF1AN protein expression, the coding sequence of JMJD6 and 
HIF1AN with a C-terminal FLAG tag sequence was amplified from mouse 
embryonic fibroblast cDNA by RT-PCR and cloned into pBABE retroviral vector 
containing a blasticidin resistance gene (219) and pcDNA3.1(-) vector (Invitrogen). 
The construct for the catalytic-inactive mutant JMJD6 (H187A/D189A) protein 
(151) was generated from the wild type JMJD6 construct by QuikChange Lightning 
site-directed mutagenesis kit (Agilent). The primers for cloning and mutagenesis 
are listed in Table A1.  
 
3.2.3 Virus preparation and transduction   
Lentivirus preparation was performed as previously described (218). Briefly, 
the shRNA lentiviral constructs were co-transfected with pLP1, pLP2 and pVSVG 
packaging vectors into 293T cells with Lipofectamine 2000 reagent (Invitrogen). 
The constructs encoding wild type JMJD6 (JMJD6-wt) and the catalytic-inactive 
mutant JMJD6 (JMJD6-mut) were individually transfected into BOSC23 cells 
(220). The viral supernatant was harvested after 48 h incubation and filtered 
through 0.45 µm syringe filter (Millipore). To infect C3H10T1/2 cells, 2 ml of the 
filtered supernatant supplemented with 4 µg/ml of polybrene (Sigma) were used to 
infect one million cells for 48 h. The infected cells were then selected in media 
containing 2.5 µg/ml puromycin (Invitrogen) or 5 µg/ml of blasticidin (Invitrogen). 
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3.2.4 Oil Red O staining  
Cells were washed once with PBS and fixed in 10% phosphate-buffered 
formalin (Fisher Scientific) overnight at room temperature. The next day, the cells 
were washed with 60% isopropanol and air dried completely. The cells were 
stained with 60% Oil-Red O (AMRESCO) for 10 min and washed extensively with 
running tap water. To quantify staining, Oil Red O was extracted with 100% 
isopropanol and measured at optical density 500 nm (OD500).  
 
3.2.5 Gene expression analysis  
Total RNA was isolated using TRIzol reagent (Invitrogen) and treated with 
DNaseI (Invitrogen) according to the manufacturer’s instructions. cDNAs were 
prepared from 1 µg of total RNA with random hexamers (Roche) and the 
Superscript III reverse transcriptase kit (Invitrogen). Real-time quantitative PCR 
was performed on a StepOne Plus real-time PCR machine with Fast SYBR green 
master mix (Applied Biosystems). The relative gene expression levels were 
calculated as 2^(Ct5S rRNA – Ctgene) and were normalized to the experimental control 
as indicated (221). The primers are listed in Table A1. 
 
3.2.6 Protein expression analysis 
Cells were washed twice with cold PBS and harvested in RIPA buffer (50 
mM Tris-HCl, pH7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, and 0.25% sodium 
deoxycholate) supplemented with protease inhibitor cocktail (Roche). Mouse 
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adipose tissue extracts were prepared as described (222). Protein concentration 
was measured using Bio-Rad protein assay. The samples were mixed with 4X 
SDS loading buffer (240 mM Tris-HCl, pH6.8, 8% SDS, 40% glycerol, 0.01% 
bromophenol blue and 10% β-mercaptoethanol) and boiled at 95°C for 10 min. 
Samples were separated on 10% SDS-PAGE and transferred onto PVDF 
membrane (Bio-Rad). The blots were blocked in 3% non-fat milk overnight at 4°C. 
After a sequential incubation with the primary antibodies and HRP-conjugated 
secondary antibodies, the blots were developed on X-ray films with ECL Western 
blotting detection reagents (GE Healthcare Life Sciences). Primary antibodies 
against JMJD6 (sc-11366), JMJD6 (sc-28348), HIF1AN (sc-26219), PPARγ (sc-
7273), C/EBPα (sc-61), C/EBPβ (sc-150), C/EBPδ (sc-151), and β-ACTIN (sc-
81178) were purchased from Santa Cruz Biotechnology. PI3-kinase p85 (ABS233) 
antibody was purchased from Millipore. The phospho-C/EBPβ (#3084) antibody 
was purchased from Cell Signaling. The anti-FLAG rabbit antisera was described 
(171). The anti-BRD2 (A302-583A), anti-BRD3 (A302-367A), and anti-BRD4 
(A301-985A50) antibodies were purchased from Bethyl Laboratories.  The 
secondary antibodies (NA9340 and NA9310) were purchased from GE Healthcare 
Life Sciences. ImageJ software was used for image quantification.  
 
3.2.7 Chromatin immunoprecipitation  
Chromatin immunoprecipitation was performed as previous described 
(223). Briefly, cells were fixed in 1% formaldehyde at room temperature for 10 min 
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and harvested as cell pellets. The cell pellets were re-suspended in cell lysis buffer 
(50 mM Tris-HCl, pH 8.0, 1% SDS, 10 mM EDTA, pH 8.0 and protease inhibitors) 
and sonicated in a Bioruptor (UCD-200, Diagenode) to obtain fragmented DNA 
sized around 500 bp. The samples were centrifuged at 12000 x g for 10 min at 4°C 
to remove insoluble debris. The supernatant containing the chromatin was pre-
cleared with 40 µl of a 50% slurry protein A beads (Protein A Sepharose CL-4B, 
GE Healthcare Life Sciences) supplemented with 0.2 mg/ml salmon sperm DNA 
(Invitrogen) and 0.5 mg/ml BSA (Invitrogen). 50 µg of DNA were 
immunoprecipitated with 4 µg of specific antibody or 20 µl of serum overnight at 
4°C. The next day, the immunocomplexes were incubated with 60 µl of a 50% 
slurry of protein A beads for 1 h at 4°C. After extensively washing, the 
immunocomplexes were eluted in 1% SDS and 1% NaHCO3. The eluted samples 
were subjected to reverse cross-linking for 4 h at 65°C. The immunoprecipitated 
DNA fragments were purified using the QIAquick PCR purification kit (QIAGEN) 
and used as templates for quantitative PCR. The fold difference of 
immunoprecipitated DNA fraction relative to input was calculated as 2^(Ctinput – 
CtChIP) (224). The primers are listed in Appendix 1. The antibodies for ChIP assays 
are C/EBPβ (sc-150), C/EBPδ (sc-151), RNA polymerase II (sc-899) and rabbit 
IgG control (sc-2027) from Santa Cruz Biotechnology. The anti-BRD4 (A301-
985A50) antibody was from Bethyl Laboratories. The anti-JMJD6 rabbit sera was 
made against a bacterial expressed GST-fusion with human JMJD6 (aa 2-414), 
which was cloned by PCR-amplification and subsequently inserted into pGEX-2T 
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plasmid. The primers for cloning are listed in Table A1. The specificity of the 
JMJD6 antisera was evaluated by western blot as shown in Figure A1. 
 
3.2.8 Immunoprecipitation 
 Cells were washed twice with cold PBS and lysed with a buffer containing 
50 mM Tris-HCl, pH7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 
protease inhibitor cocktail (Roche) on ice for 30 min. The cell lysate were pre-
cleared by  40 µl of a 50% slurry of protein A beads. 1 mg of the cell lysate was 
incubated with either 20 µl of anti-JMJD6 rabbit antisera or rabbit IgG control (sc-
2027) for 2 h at 4 °C. The samples were then incubated with 60 µl of a 50% slurry 
of protein A beads for 1 h at 4 °C. The immunocomplexes were eluted by adding 
2X SDS loading buffer and subsequently boiled at 95 °C for 10 minutes before 
SDS-PAGE and subsequent Western blotting. 
 
3.2.9 Small interfering RNA knockdown  
ON-TARGETplus mouse Cebpβ and Cepbδ siRNA SMART pools and the 
non-targeting control siRNA pool were purchased from Dharmacon GE Healthcare 
Life Sciences. The target sequences for Cepbβ mRNA were 
GAGCGACGAGUACAAGAUG, CCUUUAGACCCAUGGAAGU, 
GCACCCUGCGGAACUUGUU, and GAAAAGAGGCGUAUGUAUA. The target 
sequences for Cepbδ mRNA were CGCGGAAGGAACACGGGAA, 
AGUUGUCGGCCGAGAACGA, GUAAGGAGAUGGACGCGUU, and  
  
53 
GGCACUGGACUGCGAGAGA. Briefly, cells were plated at a density of 1.5 x 105 
cells per well in 12 well plates overnight and then transfected with siRNA pools 
using Lipofectamine 2000 in Opti-MEM medium (Invitrogen). After 4 h incubation, 
the medium was replaced with the normal growth medium for 20 h prior to 
adipogenic induction.  
 
3.2.10 Plasmid and In vitro synthesized RNA transfection  
pcDNA3-EGFP (#13031), pcDNA3.1(-) mouse C/EBPβ LAP (#12557) and 
pcDNA3.1(-) mouse C/EBPδ (#12559) were obtained from Addgene. For the 
preparation of in vitro synthesized RNA, pcDNA3.1(-) mouse C/EBPβ LAP, 
pcDNA3.1(-) mouse C/EBPδ and pcDNA3-EGFP plasmids were linearized with 
XbaI or HindIII and were in vitro transcribed with mMESSAGE mMACHINE T7 
Ultra Transcription Kit (Ambion) according to the manufacturer’s instructions. The 
capped and polyadenylated RNAs were further purified with RNA Clean and 
Concentrator Kit (Zymo Research). For transfection, 1.5 x 105 cells were plated in 
each well of 12-well plates overnight and transfected with either 2 µg of the 
plasmids or in vitro synthesized RNAs using Lipofectamine 2000 in Opti-MEM 
medium. After 4 h incubation, the media was replaced with the normal growth 
medium for 20 h prior to adipogenic induction. 
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3.2.11 Statistical Analysis 
At least three independent experiments were performed as indicated in the Figure 
legends. The values are presented as the mean ± S.E.M. Statistical analyses were 
performed using Student’s t-test with two-tailed distribution and equal variance.  
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3.3 Results 
3.3.1 JMJD6 expresses in mouse adipose tissues and adipocytes  
To understand the biological roles of JMJD6 in adipocyte differentiation, we 
first examined the expression of JMJD6 in adult adipose tissues and in 
differentiating adipocytes. Western blot analysis showed that JMJD6 protein is 
expressed in both white and brown adipose tissues from 6-week-old male and 
female C57BL/6 mice (Figure III-1A). For differentiating adipocytes, we used 
mouse multipotent mesenchymal C3H10T1/2 cells as a tissue culture model (225). 
C3H10T1/2 cells differentiate into adipocytes upon stimulation with an adipogenic 
induction media containing insulin, dexamethasone, 3-isobutyl-1-methylxanthine 
and Troglitazone. Induction of the master adipogenic regulators, PPARγ and 
C/EBPα, occurred on day 1 post-induction (Figure III-1B). JMJD6 is present in 
differentiating C3H10T1/2 adipocytes even before the onset of the differentiation 
(Figure III-1B). A transient increase of JMJD6 protein and mRNA expression was 
observed in the differentiating cells as compared to the levels at day 0 when the 
cells were undifferentiated (Figure III-1C, D). Previous work has shown that 
JMJD6 proteins form oligomers (226-229). Consistent with Western blot analysis 
and quantification of the monomer species (Figure III-1B, C), examination of a 
time course of differentiating cells indicated that the oligomeric form was present 
at the onset of differentiation and its level increased by days 2-3 post-
differentiation and decreased thereafter (Figure III-2).  Based on these results, we 
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concluded that JMJD6 is present in adult adipose tissues and expressed 
throughout the course of differentiation of C3H10T1/2 cells.  
                      
Figure III-1. JMJD6 is expressed in adipose tissues and differentiating 
C3H10T1/2 adipcoytes 
(A) Representative western blots for JMJD6 and β-ACTIN protein levels in 
adipose tissues from 6-week-old male and female C57BL/6 mice. igWAT: 
inguinal white adipose tissue; pgWAT: perigonadal white adipose tissue; 
iBAT: interscapular brown adipose tissue. (B) Representative western blots 
for JMJD6, C/EBPα and PPARγ protein levels in undifferentiated (day 0) 
and in differentiating (day 1 to 6) C3H10T1/2 cells. PI3K levels were probed 
as a loading control. (C) Quantification of JMJD6 protein levels from three 
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independent western blots. The levels of JMJD6 were normalized to PI3K 
loading control and are presented as the relative expression levels to the 
day 0 sample (S.E.M, n=3, * p<0.05; ** p<0.01). (D) Jmjd6 mRNA levels in 
the differentiating C3H10T1/2 cells were determined by real-time qPCR. 
The mRNA levels were normalized to 5s rRNA levels and the sample at day 
0 was set as 1 (S.E.M, n=3, * p<0.05; ** p<0.01). 
 
 
                                  
Figure III-2. JMJD6 oligomerization in the differentiating C3H10T1/2 
cells. 
A representative western blot for JMJD6 levels in undifferentiated (day 0) 
and in differentiating (day 1 to 6) C3H10T1/2 cells. The oligomeric JMJD6 
protein bands (~130kDa) are indicated by the red asterisk. 
 
3.3.2 Knockdown of JMJD6 impairs adipocyte differentiation 
To investigate the function of JMJD6 in adipocyte differentiation, we 
knocked down JMJD6 in C3H10T1/2 cells by introduction of small hairpin RNAs 
prior to the onset of differentiation. Two shRNAs specific for JMJD6 were used. 
shJ6-2 targets the 5’UTR and the start of the 5’ coding sequence, whereas shJ6-3 
targets the 3’UTR of Jmjd6 mRNA. The cells were induced to differentiate upon 
confluence. Adipogenic differentiation was evaluated at day 6 post-induction by 
quantifying the intracellular lipid content. Two distinct control shRNAs, a scramble 
sequence called shCtrl, and shGFP, had no effect on the adipogenic differentiation 
(Figure III-3). A significant reduction in lipid accumulation in the JMJD6 
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knockdown cells compared to the scramble shRNA control cells was observed 
(Figure III-4A, B), demonstrating that JMJD6 knockdown reduced the adipogenic 
potential of C3H10T1/2 cells. Moreover, the levels of the master regulators for 
terminal differentiation PPARγ and C/EBPα were significantly reduced in the day 6 
post-induced JMJD6 knockdown cells (Figure III-4C). Consistent with the 
reduction in protein levels, Pparγ and Cebpα mRNA expression was significantly 
reduced in the JMJD6 knockdown cells (Figure III-4D). Other adipocyte-
associated genes such as Srebp1c, Fasn, AdipoQ and Fabp4 were also down-
regulated (Figure III-4D). These results indicated that the knockdown of JMJD6 
led to a failure of differentiation of C3H10T1/2 cells due to the inability of the cells 
to activate the adipogenic gene expression program.  
                
Figure III-3. Two distinct control shRNAs do not affect the adipogenic 
differentiaiton of C3H10T1/2 cells. 
(A) Representative Oil Red O staining images, (B) the levels of Oil-Red O 
staining, and (C) the protein levels of PPARγ and C/EBPα from the cells as 
indicated.  
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3.3.3 JMJD6 regulates adipogenesis independently of its catalytic activity  
To determine whether the catalytic activity of the JmjC domain in JMJD6 is 
required for adipocyte differentiation, we used a catalytically inactive mutant 
JMJD6 that includes substitution of histidine 187 and aspartate 189 with alanine 
(151). C3H10T1/2 cells were first transduced with the retroviral constructs 
encoding FLAG-tagged wild type JMJD6 (JMJD6-wt) or catalytically inactive 
mutant JMJD6 (JMJD6-mut) or with the empty vector. Ectopically expressed 
JMJD6 protein was evaluated by Western blot analysis with an antiserum 
recognizing FLAG epitope and an antibody specific for JMJD6 (Figure III-4E). 
Consistent with the literature indicating that JMJD6 oligomerization requires JmjC 
domain catalytic activity (228), the wild type JMJD6 protein oligomerized, but the 
over-expressed mutant JMJD6 was only present as a monomer (Figure III-4E). 
The cells were subsequently transduced with the lentiviral vector containing 
shRNA to deplete endogenous JMJD6 protein. Upon adipogenic induction, a 
significant percentage of cells expressing FLAG-tagged wild type JMJD6 with 
endogenous JMJD6 depletion (JMJD6-wt/shJ6-3) differentiated into adipocytes 
(Figure III-4F). Interestingly, the cells expressing the catalytically inactive mutant 
JMJD6 (JMJD6-mut/shJ6-3) differentiated into adipocytes to the same extent as 
the cells expressing wild type JMJD6 (JMJD6-wt/shJ6-3) (Figure III-4F). 
Moreover, the protein levels of the reintroduced wild type and mutant JMJD6 
proteins were similar to levels of endogenous JMJD6 in the control cells (Figure 
III-4G, lane 4 and lane 6 compared to lane 1).  The expression levels of PPARγ 
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and C/EBPα protein were comparable in the wild type and in the mutant JMJD6 
cells (Figure III-4G, lane 4 and 6). These results suggest that the catalytic activity 
of the JmjC domain in the JMJD6 protein is dispensable for the adipogenic 
differentiation of C3H10T1/2 cells.  
            
Figure III-4. JMJD6 is required for the adipogenic differentiation of 
C3H10T1/2 cells. 
(A) Representative Oil-Red O staining images of day 6 post-induced 
C3H10T1/2 cells. Endogenous JMJD6 was knocked down by either of two 
shRNAs (shJ6-2 or shJ6-3). A scramble shRNA construct (shCtrl) was used 
a control. (B) Quantification of Oil Red O staining. The values are presented 
as the average of optical density at 500 nm (OD500) from three independent 
experiments (S.E.M, n=3, ** p<0.01). (C) Representative western blots for 
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JMJD6, C/EBPα and PPARγ protein levels in the day 6 post-induced cells 
as indicated. PI3K levels were probed as a loading control. (D) The mRNA 
levels of adipocyte-associated genes in the day 6 post-differentiated cells. 
The individual mRNA levels were normalized to 5s rRNA levels. The 
normalized expression levels of the control cells were set as 1 (S.E.M, n=3, 
* p<0.05; ** p<0.01). (E) Representative western blots of the ectopically 
expressed wild type JMJD6 (JMJD6-wt) and catalytic-inactive mutant 
JMJD6 (JMJD6-mut) in C3H10T1/2 cells prior to differentiation. The blots 
were probed with either anti-FLAG antiserum or a JMJD6-specific antibody. 
(F) Representative Oil Red O staining images of day 6 post-differentiated 
cells as indicated. The C3H10T1/2 cells expressing either wild type JMJD6 
(JMJD6-wt) or catalytic-inactive mutant (JMJD6-mut) or empty vector were 
subsequently transduced with lentiviral constructs containing either a 
scramble shRNA control (shCtrl) or a shRNA targeting the 3’UTR of Jmjd6 
mRNA (shJ6-3). (G) Representative western blots for JMJD6, C/EBPα and 
PPARγ protein levels in day 6 post-induced cells as indicated. 
 
3.3.4 Knockdown of JMJD6 reduces C/EBPβ  and C/EBPδ expression  
To determine the causes of the differentiation defect in the JMJD6 
knockdown cells, we analyzed the activation of Pparγ and Cebpα genes, which is 
crucial for terminal differentiation. C/EBPβ and C/EBPδ are early adipogenic 
regulators that collaborate to activate Pparγ and Cebpα transcription during the 
early stage of differentiation (183,191). By examining the expression of C/EBPβ 
and C/EBPδ, we found that JMJD6 knockdown resulted in a reduction of C/EBPβ 
and C/EBPδ protein expression at 3 h post-induction (Figure III-5A). However, we 
did not observe any effect of JMJD6 knockdown on Cebpβ and Cebpδ mRNA 
levels (Figure III-5B), which suggests that JMJD6 is involved in the post-
transcriptional control of C/EBPβ and C/EBPδ expression. Both Cebpβ and Cebpδ 
are intronless genes. Therefore, the known function of JMJD6 in RNA splicing 
would not be a direct mechanism that caused the reduction C/EBPβ and C/EBPδ 
protein expression. We examined the protein stability of C/EBPβ and C/EBPδ by 
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cycloheximide treatment and Western blot analysis. Protein samples were 
collected for up to 5 hours in the presence of cycloheximide. No significant 
difference was detected in the degradation rate of C/EBPβ or C/EBPδ between the 
JMJD6 knockdown cells and the control cells (Figure III-6). Therefore, JMJD6 
knockdown had no effect on C/EBPβ and C/EBPδ stability. 
       
Figure III-5. Down-regulation of C/EBPβ  and C/EBPδ  by knockdown of 
JMJD6. 
(A) Representative western blots for C/EBPβ and C/EBPδ protein levels in 
the 3 h post-induced control cells (shCtrl) and the JMJD6 knockdown cells 
(shJ6-2 and shJ6-3). PI3K levels were probed as a loading control. LAP 
and LIP represent different isoforms of C/EBPβ (B) Cebpβ and Cebpδ 
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mRNA levels in the 3 h post-induced cells. The normalized expression 
levels of the control cells were set as 1. The values are presented as the 
average of relative expression levels with standard error (S.E.M, n=3, ns: 
not significant). (C-D) Representative western blots for C/EBPβ and 
C/EBPδ protein levels in 3 h post-induced cells that were pre-treated with 
the indicated siRNAs for 24 h prior to adipogenic induction. β-ACTIN levels 
were probed as a loading control. (E) Representative Oil Red O staining 
images of day 6 post-induced C3H10T1/2 cells with siRNA treatment as 
indicated. (F) Quantification of Oil Red O staining. The values are 
presented as the average of optical density at 500 nm (OD500) from three 
independent experiments (S.E.M, n=3, * p<0.05, ** p<0.01). 
 
              
Figure III-6. Knockdown of JMJD6 has no effect on C/EBPβ  and 
C/EBPδ  protein stability. 
(A) Representative western blots for C/EBPβ and C/EBPδ protein levels 
upon cycloheximide treatment. The 3 h post-induction cells were treated 
with 100 µg/ml cycloheximide. The total cell lysates were harvested every 
hour for 5 additional hours in the presence of cycloheximide. β-ACTIN was 
probed as a loading control. (B-D) C/EBPβ(LAP), C/EBPβ(LIP) and C/EBPδ 
protein levels in two independent experiments (n=2) were quantified by 
ImageJ. The protein levels were normalized to β-ACTIN loading control and 
were presented as the relative expression levels to the 0 h sample (mean, 
n=2).  
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Since JMJD6 knockdown did not completely abolish C/EBPβ and C/EBPδ 
expression, we examined whether suboptimal levels of C/EBPβ and C/EBPδ were 
sufficient to cause the differentiation deficiency. C3H10T1/2 cells were pre-treated 
with the siRNA targeting Cebpβ and Cebpδ mRNA 24 h prior to adipogenic 
induction. C/EBPβ and C/EBPδ protein levels were examined in 3 h post-induced 
cells (Figure III-5C, D). At a concentration of 50 nM, the siRNA treatment caused 
only a modest decrease in C/EBPβ and C/EBPδ protein levels. However, the 
adipogenic differentiation of C3H10T1/2 was significantly blocked (Figure III-5E, 
F). These results support the conclusion that the decease in C/EBPβ and C/EBPδ 
protein expression contributes to the differentiation deficiency in JMJD6 
knockdown cells. 
3.3.5 Knockdown of JMJD6 decreases C/EBPβ and RNA polymerase ll 
binding at the  Pparγ2 and Cebpα gene loci  
A previous study suggested that C/EBPβ functions as a pioneer 
transcription factor for the activation of the transcriptional program during the early 
stages of adipocyte differentiation (192). Since phosphorylation of C/EBPβ 
modulates its transcriptional activity (230), we further examined the effect of 
JMJD6 knockdown on the levels of C/EBPβ and phosphorylated C/EBPβ at 
threonine 188 in the differentiating cells. We found that JMJD6 knockdown 
reduced C/EBPβ levels throughout the first 48 h of differentiation (Figure III-7A), 
which is consistent with the previous results (Figure III-5A). Moreover, the level of 
C/EBPβ phosphorylation was directly proportional to the level of total C/EBPβ both 
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in shCtrl and shJ6-3 cells (Figure III-7A and Figure III-8), indicating that JMJD6 
was not specifically affecting C/EBPβ phosphorylation of threonine 188. We 
therefore explored the possibility that reduced C/EBPβ protein levels might directly 
contribute to the activation of the Pparγ2 and Cebpα genes by analyzing its 
binding to the corresponding promoter regions. As expected, ChIP assays showed 
that the binding of C/EBPβ was reduced at the Pparγ2 and Cebpα proximal 
promoters in the JMJD6 knockdown cells upon adipogenic induction (Figure III-
7B, C), which correlates with the inhibition of Pparγ2 and Cebpα expression. It has 
been shown that JMJD6 directly contributes to RNA polymerase II transcription 
through binding to distal enhancers (142). We therefore examined the binding of 
JMJD6 and RNA polymerase II at the Pparγ2 and Cebpα loci and their putative 
enhancers. For calling the putative enhancers, we searched published datasets for 
genomic regions that were enriched with DNAse I hypersensitivity (DHS), MED1, 
p300, and BRG1 binding, and H3K4me1/2 and H3K27Ac incorporation but with 
low levels of H3K4me3 incorporation (Figure III-9) (201,202). The -9.5kb, +96kb, 
and +100kb regions of the Pparγ2 locus and +37kb regions of the Cepbα were 
previously called as putative enhancers in immortalized brown preadipocytes 
(201). ChIP-qPCR results showed that the binding of JMJD6 increased upon 
differentiation across the Pparγ2 and Cebpα genomic loci (Figure III-10A, B). In 
addition, the binding of JMJD6 and RNA polymerase II at most of the sequences 
examined was decreased in the JMJD6 knockdown cells (Figure III-7D to G). 
These data suggest that the failure of Pparγ2 and Cebpα gene activation caused 
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by the JMJD6 knockdown is likely a consequence of the reduced binding of 
C/EBPβ, JMJD6, and RNA polymerase II at these genomic loci. 
           
Figure III-7 Knockdown of JMJD6 reduced C/EBPβ  and RNA 
polymerase II occupancy at the Pparγ2 and Cebpα loci.  
(A) Representative western blots for the levels of C/EBPβ and 
phosphorylated C/EBPβ at threonine 188 in the control cells (shCtrl) and in 
the JMJD6 knockdown cells (shJ6-3) throughout the early phase of 
differentiation. PI3K levels were probed as a loading control. (B) ChIP of 
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C/EBPβ at the Pparγ2 and Cebpα proximal promoters. (C) ChIP of rabbit 
IgG for negative control. (D-E) ChIP of JMJD6 and (F-G) ChIP of RNA 
polymerase II at the Pparγ2 and Cebpα loci and nearby putative enhancers. 
The values are presented as the average % input from at least three 
independent experiments (S.E.M, n≥3, * p<0.05, ** p<0.01). 
 
 
 
 
Figure III-8 The phosphorylated C/EBPβ is proportional to the total 
C/EBPβ in both control and JMJD6 knockdown cells. 
The levels of C/EBPβ and phosphorylated C/EBPβ in Figure III-7A were 
quantified by ImageJ.  
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Figure III-9. Calling the putative enhancers using the published DHS-
seq and ChIP-seq datasets. 
The DHS-seq datasets (GSE27826) and ChIP-seq datasets (GSE56872 
and GSE50466) were uploaded to Integrative Genomics Viewer. (A) 
Screenshot of Pparγ2 locus. (B) Screenshot of Cebpα locus. Blue bars 
indicate the regions for primer design. P: promoter; E: putative enhancer; 
GB: gene body. 
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Figure III-10. Inducible binding of JMJD6 at the Pparγ2 and Cebpα loci 
during differentiation.  
(A-B) ChIP of JMJD6 at the Pparγ2 and Cebpα loci in the undifferentiated 
(0h post-induced) and in the differentiating (24h post-induced) C3H10T1/2 
cells. The values are presented as the average % input from three 
independent experiments (S.E.M, n=3, *p<0.05, **p<0.01). (C) The binding 
of JMJD6 at the Cebpβ and Cebpδ promoters was examined as negative 
controls. The values are presented as the average % input from three 
independent experiments (S.E.M, n=3, ns: not significant)  
 
3.3.6 Ectopic expression of C/EBPβ  and C/EBPδ  is not sufficient to rescue 
the differentiation deficiency  
To determine whether the JMJD6-dependent defects in Pparγ2 and Cebpα 
gene activation were entirely related to the decrease in C/EBPβ and C/EBPδ 
protein levels, we attempted to rescue the adipogenic differentiation in the JMJD6 
knockdown cells by ectopically expressing C/EBPβ and C/EBPδ. Transient 
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transfection of the plasmids encoding C/EBPβ (LAP isoform) and C/EBPδ protein 
into the scramble control cells resulted in robust expression of C/EBPβ and 
C/EBPδ (Figure III-11A). However, the JMJD6 knockdown cells failed to express 
these proteins (Figure III-11A), even though the plasmid-derived mRNAs were 
present in the JMJD6 knockdown cells (Figure III-12A, B).  These data suggest 
that the post-transcriptional mechanism by which JMJD6 regulates endogenous 
C/EBPβ and C/EBPδ also regulates the ectopic expression of these proteins. To 
bypass the post-transcriptional defects resulting from the knockdown of JMJD6, 
we introduced Cebpβ and Cebpδ mRNAs that were synthesized in vitro (Figure III-
12C, D). This procedure generated equivalent protein expression both in the 
JMJD6 knockdown cells and in the control cells (Figure III-11B). We then sought 
to determine whether the introduction of Cebpβ and Cebpδ mRNA could rescue 
the differentiation deficiency resulting from JMJD6 knockdown. For the mRNA 
transfection control, we chose in vitro transcribed EGFP mRNA because of the 
length similarity to Cebpβ and Cebpδ mRNA and the minimal effect of EGFP on 
the transcriptional program. As shown by Oil Red O staining, ectopic expression of 
Cebpβ and/or Cebpδ mRNA was not sufficient to rescue the differentiation 
deficiency (Figure III-11C). The JMJD6 knockdown cells transfected with a 
combination of Cebpβ and Cebpδ mRNA failed to express endogenous Pparγ2 
and Cebpα mRNA to the levels observed in the control cells (Figure III-11D). 
Based on these results, we conclude that the JMJD6 knockdown cells must have 
multiple defects in Pparγ2 and Cepbα gene activation. Since JMJD6 was present 
at the Pparγ2 and Cepbα genomic loci (Figure III-7D, E), we speculated that 
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JMJD6 might directly contribute to the transcriptional activation of Pparγ2 and 
Cepbα.   
 
Figure III-11. Ectopic expression of C/EBPβ  and C/EBPδ  is not 
sufficient to rescue the differentiation deficiency. 
(A) Representative western blots for the levels of C/EBPβ, C/EBPδ and 
JMJD6 protein expression in the control cells (shCtrl) and in the JMJD6 
knockdown cells (shJ6-2 and shJ6-3) 24 h after transfection with the 
plasmids encoding C/EBPβ(LAP) and C/EBPδ protein. An empty vector was 
used as a transfection control. (B) C/EBPβ, C/EBPδ and JMJD6 protein 
expression in the cells 24 h after transfection with in vitro synthesized 
Cebpβ and Cebpδ mRNA. In vitro synthesized EGFP mRNA was used as a 
transfection control. (C) Representative Oil Red O staining images of the 
day 6 post-induced cells as indicated. (D) Pparγ2 and Cebpα mRNA levels 
in the day 6 post-induced cells that were transfected with EGFP mRNA or a 
combination of Cebpβ and Cebpδ mRNA (Cebpβ+δ) as indicated. The 
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values are presented as the average of relative expression levels with 
standard error (S.E.M, n=3, * p<0.05; ** p<0.01, ns: not significant).  
      
  
Figure III-12. Ectopic expression of C/EBPβ  and C/EBPδ  by 
introduction of plasmids or in vitro synthesized RNAs. 
(A-B) Cebpβ and Cebpδ mRNA levels in the plasmid-transfected cells. The 
cells were transfected with the plasmids encoding either C/EBPβ or C/EBPδ 
or empty vector for 24 h and then harvested for gene expression analysis. 
(C-D) Cebpβ and Cebpδ mRNA levels in the RNA-transfected cells. The 
cells were transfected with the in vitro synthesis mRNA encoding either 
C/EBPβ or C/EBPδ for 24 h and harvested for gene expression analysis. 
The values presented are the average relative expression levels from 
technical replicates of the matching RNA samples from the western blot 
experiment presented in Figure. III-11 A-B. 
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3.3.7 The BET protein inhibitor JQ1 inhibits the transcriptional program for 
adipocyte differentiation  
JMJD6 has no characterized DNA binding domain (231) and also lacks 
DNA binding ability in vitro (160). Studies have shown that JMJD6 physically 
interacts with the chromatin reader proteins BRD4 and BRD2 (142,232). To 
determine the mechanisms by which JMJD6 binds to the genomic loci and directly 
controls Pparγ2 and Cepbα gene activation, we targeted the chromatin reader for 
JMJD6 by the BET protein-specific inhibitor JQ1 (233). We found that JQ1 
treatment significantly inhibited adipogenic differentiation at a 1 µM dose (Figure 
III-13A, B). By analyzing the expression of adipogenic regulators, we found that 
JQ1 treatment blocked PPARγ and C/EBPα protein expression (Figure III-13C). 
Unlike in the JMJD6 knockdown cells, JQ1 had no effect on C/EBPβ and C/EBPδ 
levels at either 3 or 24 hours post-induction (Figure III-13C). Consistent with the 
protein analysis, JQ1 treatment inhibited the expression of Pparγ2 and Cebpα 
mRNAs without or with minimal effect on Cebpβ and Cebpδ mRNA expression, 
respectively (Figure III-13D). The data indicate that the inhibition of adipogenic 
differentiation by JQ1 occurs via a mechanism that affects PPARγ2 and C/EBPα 
expression without affecting expression of the C/EBPβ and C/EBPδ. Though JQ1 
affects neither the expression of JMJD6 (Figure III-13C) nor the interaction of 
JMJD6 with BRD4 (Figure III-14), ChIP experiments showed that JQ1 treatment 
reduced the binding of JMJD6, BRD4, and RNA polymerase II at the Pparγ2 and 
Cepbα loci and their putative enhancers (Figure III-15A to F), thereby providing a 
mechanism for the inhibition of Pparγ2 and Cebpα gene expression. JQ1 
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treatment did not affect the binding of C/EBPβ and C/EBPδ at the Pparγ2 and 
Cebpα promoter regions (Figure III-15G, H). These results indicate that BRD4-
mediated JMJD6 chromatin binding at the Pparγ2 and Cepbα genomic loci 
contributes to gene activation during differentiation.  
 
Figure III-13. The BET protein inhibitor JQ1 inhibits the adipogenic 
differentiation of C3H10T1/2 cells. 
(A) Representative Oil Red O staining images of day 6 post-induced 
C3H10T1/2 cells treated with JQ1 or DMSO. The treatment was performed 
in the first 48 hours during the adipogenic induction. (B) Quantification of Oil 
Red O staining. The values are presented as the average of optical density 
at 500 nm (OD500) from three independent experiments (S.E.M, n=3, * 
p<0.05, ** p<0.01). (C) Representative western blots for the indicated 
proteins in the 3 h and 24 h post-induced cells in the presence of 1 µM JQ1 
or DMSO as a vehicle control. (D) The mRNA levels of the indicated genes 
in the 3 h and 24 h post-induced cells in the presence of 1 µM JQ1 or 
DMSO. The values are presented as the average of relative expression 
levels from three independent experiments with standard error (S.E.M, n=3, 
* p<0.05; ** p<0.01, ns: not significant). 
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Figure III-14. BRD4 is immunoprecipitated with JMJD6. 
Endogenous JMJD6 proteins in day1 post-induced C3H10T1/2 cells with 
and without JQ1 treatment were immunoprecipitated. The eluted samples 
were run on 8% SDS-PAGE for western blotting. The blots were probed 
with antibodies against JMJD6 (sc-28349), mouse IgG (NA9310), BRD4 
(A301-985A50), C/EBPβ (sc-150), BRD2 (A302-583A), and BRD3 (A302-
367A). 
 
 
Collectively, the data support the conclusion that JMDJ6 acts as both a 
post-transcriptional and a transcriptional regulator during adipogenesis. A 
schematic diagram summarizing our findings is presented in Figure III-16. 
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Figure III-15. JQ1 treatment reduces the binding of JMJD6 and RNA 
polymerase II at the Pparγ2 and Cebpα loci. 
(A-B) ChIP of JMJD6, (C-D) ChIP of BRD4, and (E-F) ChIP of RNA 
polymerase II at the Pparγ2 and Cebpα loci and nearby putative enhancers 
in 24 h post-induced C3H10T1/2 cells in the presence of 1µM JQ1 or 
DMSO. (G) ChIP of C/EBPβ and (H) ChIP of C/EBPδ at the Pparγ2 and 
Cebpα proximal promoters in 24 h post-induced C3H10T1/2 cells. The 
values are presented as the average % input from four independent 
experiments (S.E.M, n = 4, * p<0.05, ** p<0.01, ns: not significant). For 
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negative control, ChIP of rabbit IgG was performed under the same 
conditions. The average % input from rabbit IgG ChIPs was below 0.05% in 
all cases (data not shown). 
 
 
  
 
Figure III-16. The dual functions of JMJD6 in control of adipogenic 
gene expression. 
(A) JMJD6 participates in the post-transcriptional regulation of C/EBPβ and 
C/EBPδ and transcriptional activation of Ppaγ2 and Cebpα genes. (B) Upon 
JMJD6 knockdown, dual functions of JMJD6 are compromised, and that 
results in a reduction of C/EBPβ and C/EBPδ protein levels and the mRNA 
levels from the Ppaγ2 and Cebpα genes. (C) Treatment of JQ1 blocks the 
transcriptional activation function of JMJD6 without an effect on C/EBPβ 
and C/EBPδ protein levels. 
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3.4 Discussion  
The effect of JMJD6 knockdown on C/EBPβ and C/EBPδ expression 
suggests a novel role of JMJD6 in the post-translational control of gene 
expression. We had determined that JMJD6 knockdown had no effect on C/EBPβ 
and C/EBPδ protein stability, and since both Cebpβ and Cebpδ are intronless 
genes, the reduction of C/EBPβ and C/EBPδ expression cannot be due to a defect 
in splicing of these two transcripts. Moreover, the general translation machinery is 
unlikely affected, because the in vitro synthesized Cebpβ and Cebpδ mRNA can 
be translated in the JMJD6 knockdown cells. Therefore, we concluded that JMJD6 
promotes C/EBPβ and C/EBPδ expression at one or more steps between RNA 
synthesis and translation. The known JMJD6 interacting proteins are mostly 
involved in RNA processing (151). In addition, structural and biochemical 
characterization of JMJD6 also suggests a broad RNA binding capability (160). 
Perhaps JMJD6 is a part of Cebpβ and Cebpδ messenger ribonucleoprotein 
particles (mRNPs) and is involved in the assembly, processing, remodeling and 
localization of these mRNPs. Alternatively, JMJD6 might facilitate mRNA binding 
to ribosomes, which would be supported by the known interaction with ribosomal 
proteins and translation initiation factors (151,229). Taken together, we propose 
that JMJD6 plays multiple roles in post-transcriptional regulation of gene 
expression, regulating splicing on intron containing genes and as well as a second 
function related to other aspects of RNA processing. To get insight on how JMJD6 
is involved in the various steps of mRNA metabolism in the context of 
adipogenesis, it would be interesting to identify and characterize the interacting 
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protein partners as well as the associated RNA species with unbiased approaches 
such as immunoprecipitation followed by mass spectrometry or deep sequencing.   
 
Though our studies demonstrated that JMJD6 dependent regulation of 
C/EBPβ and C/EBPδ expression contributes to the activation of the lineage 
determinants Pparγ2 and Cebpα, the work also indicates that this function is not 
sufficient to drive Pparγ2 and Cebpα expression and adipogenic differentiation.  
Thus there are additional roles for JMJD6 in promoting adipogenesis. Our ChIP 
results showed that JQ1 treatment caused the loss of JMJD6 binding at the Pparγ2 
and Cebpα loci in a manner independent of controlling C/EBPβ and C/EBPδ 
expression. Therefore, JMJD6 likely directly contributes to the transcriptional 
activation of Pparγ2 and Cebpα genes, perhaps in cooperation with the known 
JMJD6 interacting protein, BRD4. Consistent with this hypothesis, treatment of 
cells with JQ1 caused a decrease in BRD4 and RNA polymerase II occupancy at 
the examined loci. Though previous work by others connected JMJD6 to the 
release of RNA polymerase II pausing (142), it appears that in the context of 
Pparγ2 and Cebpα activation, JMJD6 may also promote RNA polymerase II 
recruitment. The decrease of RNA polymerase II binding at the putative enhancers 
near the Pparγ2 and Cebpα loci indicates that both JMJD6 knockdown and JQ1 
treatment might not only inhibit the transcription of Pparγ2 and Cebpα genes but 
also the enhancer-derived RNAs (eRNAs). Noncoding eRNA transcripts have 
been indentified in a number of cell types including adipocytes (203,234). Although 
the function of eRNAs are not fully understood, several lines of evidence suggest 
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the roles of eRNA in promoting enhancer-promoter chromatin looping (235) and 
RNA polymerase II recruitment at promoters and gene bodies (236,237). 
Therefore the contributions of JMJD6 to transcription might occur via both 
promoter and enhancer sequences.  
 
Studies examining the effects of JQ1 on RNA polymerase II transcription 
have indicated that JQ1 selectively binds to the BRD4 bromodomain, and prevents 
the genomic binding by BRD4 and its associated factors, pTEFb and Mediator 
(238,239). Our study indicates that JMJD6 is one of the BRD4-associated proteins 
in the differentiating cells (Figure III-14), and the binding of JMJD6 at the genomic 
loci is prevented by JQ1 (Figure III-15). However, the inhibitory effects of JQ1 on 
the adipogenic transcription program might be pleiotrophic, because BRD4 
interacts with multiple transcription factors and chromatin regulators in addition to 
acetylated histones through its bromodomain (240). Furthermore, it is important to 
note that JQ1 has high affinity for the bromodomains of BRD2, BRD3, BRD4 and 
BRDT (233). Except for testes/oocyte-specific BRDT, BRD2, BRD3, BRD4 might 
all contribute the gene transcription program during adipogenic differentiation, 
possibly because these BET proteins facilitate transcriptional elongation through 
acetylated nucleosomes (241,242). Further complicating matters, BRD2 shows 
anti-adipogenic function in a hypomorphic mouse model as well as in 3T3-L1 
preadipocytes (243,244). It is still unclear how BRD2 represses Pparγ2 gene 
expression, but the evidence indicated that BRD2 associates with PPARγ and 
represses the ability of PPARγ to activate downstream target genes (243). There 
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may therefore be a regulatory balance between positive and negatively acting BET 
proteins. Although we did not indentify any interaction of JMJD6 with BRD2 and 
BRD3 at the time point we assayed in the differentiating cells by co-
immunoprecipitation (Figure III-14), since JMJD6 potentially interacts with both 
BRD2 and BRD4 (142,232), it is possible that JMJD6 collaborates with these 
distinct chromatin readers in a temporal-and spatial-dependent manner that 
differentially regulates the adipogenic transcriptional program.   
 
JMJD6 was originally identified as an arginine demethylase (141) but 
subsequent work from different groups has been contradictory; some studies 
support the original findings while others do not and suggest that JMJD6 instead 
acts as a lysine hydroxylase (142,144,151,157,228,245).  Our study demonstrated 
that the adipogenic function of JMJD6 is independent of JmjC domain activity. A 
recent study also reported a JmjC domain independent function of JMJD6 in the 
splicing of a reporter gene (159). Thus while JMJD6 has the potential to post-
translationally modify chromatin and/or proteins involved in transcription, splicing, 
or any other cellular process, any such activity is not required for adipogenic 
differentiation, or, at best, contributes to the process in a non-essential manner.  
Given the diverse roles described for JMJD6, perhaps it functions as a scaffold 
protein that facilitates the localization and functions of other regulatory proteins.  
 
The idea of JMJD6 function that is independent of JmjC domain catalytic 
activity raises the question of what JMJD6 domains mediate its functions. In 
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addition to the JmjC domain, JMJD6 has a polyserine domain, multiple nuclear 
localization sequences, a nuclear export sequences, an AT-hook DNA binding 
motif, and a sumoylation site (231,246). To date, only the polyserine domain and 
nuclear localization sequences have been functionally evaluated (229,246,247). 
We attempted to identify regions of JMJD6 that are necessary for adipogenic 
differentiation by ectopically expressing a series of truncated JMJD6 proteins in 
C3H10T1/2 cells. However, the expression levels of these truncated JMJD6 
proteins were either very low or not detectable (Figure III-17). These findings are 
consistent with the work of others who have also reported that truncations and 
deletions in JMJD6 decrease protein stability or form protein aggregates when 
they are ectopically expressed (227). Therefore, the domain(s) of JMJD6 
necessary for the adipogenic function is still unclear. A systematic structure-
function study using point mutations or small deletions would be necessary to 
identify the JmjC domain-independent functions of JMJD6.  
 
  
83 
 
Figure III-17. Ectopic expression of JMJD6 proteins in C3H10T1/2 
cells. 
(A) Scheme of the full-length wild type, catalytic-inactive and truncated 
JMJD6 mutants. The DNA sequences encoding the truncated proteins were 
PCR amplified and cloned into a pBABE vector as the same as for the wild 
type and catalytic-inactive JMJD6 mutant. (B) A representative western blot 
for the expression of JMJD6 proteins in C3H10T1/2 cells. The blot was 
probed with a serum recognizing FLAG sequence and re-probed with an 
antibody for β-ACTIN as a loading control.   
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CHAPTER IV  
Discussion and Conclusions 
 
4.1 Role of PRMTs in adipocyte differentiation and function   
In the context of adipocyte differentiation, PRMT5 and PRMT4 are 
transcriptional co-activators for PPARγ and PPARγ target genes (55,79). The 
results presented in this thesis suggest that PRMT7 is not essential for the 
differentiation of adipocytes. The role of other PRMTs in adipocyte differentiation 
remains to be elucidated. PRMT2, PRMT3, PRMT6 deficient mice are viable with 
no developmental defects (49-51,59) and PRMT8 is expressed specifically in brain 
(17). Therefore, these PRMTs are unlikely to affect adipogenic differentiation.  
 
PRMT1 might play a role in adipocyte differentiation, though the direct 
connection between PRMT1 and differentiation has not been examined 
experimentally. The transcription factor FOXO1 is a negative regulator for 
adipocyte differentiation (248). Exposure of preadipocyte to insulin induces Akt-
dependent phosphorylation of FOXO1 and its nuclear export. Methylation of 
FOXO1 by PRMT1 prevents the Akt-dependent phosphorylation, thereby 
increases its nuclear accumulation and function (101), which is known to prevent 
adipocyte differentiation. PRMT1 might also have a role in the formation of brown 
adipocytes, because PRMT1 methylates transcriptional co-regulator PGC-1α (110) 
and RIP140 (111,249). PGC-1α is a PPARγ-associated transcriptional co-activator 
that activates the genes involved in mitochondrial biogenesis and adaptive 
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thermogenesis (250). RIP140 acts a co-repressor that represses the genes 
involved in energy expenditure (251-253). Methylation of PGC-1α by PRMT1 
stimulates its co-activator activity(110), whereas methylation of RIP140 
suppresses its co-repressor function (111,249). Therefore, PRMT1 might promote 
brown adipocyte formation or white adipocytes browning by methylating PGC-1α 
and RIP140.  
 
The biological roles of PRMTs in post-differentiated adipocytes are largely 
unknown. Metabolic diseases, including obesity and diabetes, are tightly 
associated with adipocyte dysfunctions such as changes in lipid storage and 
mobilization, insulin sensitivity, cytokine and peptide hormone production (254). 
The limited efficiency of plasmid transfection and viral transduction in mature 
adipocytes makes it difficult to perform gain-of-function or loss-of-function study. In 
order to examine the roles of PRMTs in mature adipocytes, alternative approaches 
might be required. Several chemical and peptide-based PRMT inhibitors are 
available, though the specificity and cellular activity of the current PRMT inhibitors 
remains to be improved (1,65). It would be amenable to treat cultured adipocytes 
with the inhibitors to see whether inhibition of PRMTs causes any molecular and 
phenotypic changes such as gene expression, cytokine secretion, and lipid 
accumulation. Additionally creation of inducible knockout models for individual 
PRMTs would be ideal tools for studying the specific roles of PRMTs in adipose 
tissues. The effect of tissue-specific knockout might be observed in a normal 
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physiological condition or under a pathological condition such as diet-induced 
obesity.  
 
4.2 Biological roles and enzymatic functions of PRMT7   
Though PRMT7 is not required for the adipocyte differentiation and cell 
proliferation of C3H10T1/2 cells, it has significant roles in development and 
survival of organisms. PRMT7 orthologs were found in eukaryotes including Mus 
musculus, Xenopus laevis, Drosophila melanogaster, C. elegans and Arabiddopsis 
thaliana, but not in yeasts or in prokaryotes (22). Loss of PRMT7 ortholog Dart7 in 
D. melanogaster leads to pupal lethality (255). PRMT7 knockout mice die within 5-
10 days after birth (33). The causes of lethality are not characterized. Defective B-
cell development and humoral immunity were identified in mice with a B-cell 
specific knockout of PRMT7. However, these mice seem to live much longer as 
compared to the whole body PRMT7 knockout mice (5 to 10 months or longer vs. 
5 to 10 days) (33). Therefore, additional roles of PRMT7 might exist in vivo. 
Indeed, a study suggests that PRMT7 might be required for cellular pluripotency, 
because the expression of PRMT7 decreases as embryonic stem cells and 
embryonic germ cells differentiate (216). Another study showed that PRMT7 
represses neuronal gene expression and differentiation (87). PRMT7 also 
participate in the cellular responses to DNA damage (31). Therefore, future studies 
are necessary to connect the context-dependent functions of PRMT7 to its 
systematic role in organisms.       
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The type of methylation that PRMT7 catalyzes remains controversial. 
Although many studies have linked PRMT7 to symmetrical dimethylation on 
substrates in vivo (28,30-33,87,128), the in vitro characterization of PRMT7 activity 
is contradictory. The Pestka group showed that the recombinant human PRMT7 is 
capable of forming symmetrical dimethylation on the common PRMT substrates 
including histones, myelin basic protein, and Sm proteins (26). The methylation 
products were analyzed by thin-layer chromatography (TLC), demonstrating a type 
II activity of PRMT7. The resolution of TLC-based assay and the possible 
contamination with PRMT5 during immunoprecipitation procedure make these 
results questionable (23). Although the purified FLAG-PRMT7 was not associated 
with the ectopically expressed HA-PRMT5, the potential interaction of FLAG-
PRMT7 with the endogenous PRMT5 cannot be ruled out, because PRMT5 is 
known to interact with the anti-FLAG M2 antibody (256). Additionally, the lack of a 
negative control involving a PRMT7 catalytic mutant in the methyltransferase 
activity assay makes it difficult to conclude that the methylation on the substrates 
resulted only from the PRMT7 activity. 
 
In contrast, Clarke and colleagues determined that recombinant human and 
mouse PRMT7 only catalyze monomethylation in vitro by high-resolution cation 
exchange chromatography (22-25). Their results are consistent with the 
characterization of PRMT7 homologue in Trypanosoma Brucei (257). 
Crystallographic analyses also indicated that T. Brucei PRMT7 (TbPRMT7) and C. 
elegans PRMT7 (cePRMT7) contains a narrow arginine-binding pocket, which can 
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only accommodate unmethylated arginine as a substrate for methylation (35,258). 
The mouse PRMT7 (mPRMT7) may bind monomethylarginine (40). However, 
mPRMT7 only catalyzes monomethylation in vitro (24). In addition, PRMT7 targets 
a RXR sequence within lysine and arginine-rich regions instead of the common 
motifs for other PRMTs (24,25). These findings suggest the unique substrate 
specificity and type III activity of PRMT7. In this regard, both type I and type II 
PRMTs might not be able to compensate the function of PRMT7.  
 
More biochemical and structural characterization is required to fully 
understand PRMT7’s catalytic activity and substrate specificity. In addition, the 
connection between PRMT7 and cellular levels of MMA are not established. MMA 
was identified on a large set of proteins involved in RNA processing and 
transcriptional regulation (8,9). Transcriptional inhibition using Actinomycin D 
alters the levels of MMA without changes in ADMA and SDMA on the substrates, 
indicating MMA represent a distinct biological mark rather than an intermediate of 
dimethylation (9). Thus, it would be interesting to determine whether these MMA 
marks are catalyzed by PRMT7 and the functional consequence of 
monomethylation on substrates.  
 
4.3 Adipogenic function of JMJD6 and beyond  
 The investigation of JMJD6 leads to the conclusion that JMJD6 is required 
for adipocyte differentiation. Surprisingly, the data suggests that the participation 
of JMJD6 in the differentiation is independent of its enzymatic activity. This finding 
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and the previous report on JMJD6 function in splicing (159) suggest that JMJD6 
may instead acts as a scaffold protein for both transcription and RNA splicing. The 
differences between enzymatic and scaffold functions in gene regulation might be 
examined by transcriptome analysis on the knockout and the enzymatic dead 
knock-in models for JMJD6. Moreover, since JMJD6 interacts with the multiple 
proteins involved in transcriptional regulation and RNA processing 
(142,151,159,229), it is likely that JMJD6 recruits its binding partners to the 
chromatin to facilitate these processes. This hypothesis can be examined by ChIP 
assays for factor binding at Pparγ and Cebpα gene loci.   
 
  The chromatin association of JMJD6 is mediated by BRD4 and that is 
crucial for the expression of the Pparγ and Cebpα genes during adipocyte 
differentiation. The results are consistent with the previous study showing BRD4 
and JMJD6 cooperates to regulate gene expression in HEK293T and HeLa cells 
(142). However, the previous study connected the transcriptional function of 
JMJD6 to its dual demethylase activities targeting both histone H4R3 and 7SK 
RNA, which is inconsistent with my results showing that the enzymatic activity is 
not essential. Moreover, unlike their results, neither overexpression nor 
knockdown of JMJD6 affected the symmetrical dimethylation of histone H4R3 
(Figure A2). Therefore, further research is required to understand the 
mechanisms by which JMJD6 facilitates gene expression in the context of 
adipogenesis. JMJD6 directly interacts with CDK9 (142), a kinase component of P-
TEFb complex. One possible scenario is that JMJD6-BRD4 complex competes 
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with HEXIM1/7SK snRNP complex for CDK9 binding independently of JMJD6’s 
enzymatic activity. HEXIM1/7SK snRNP is a general transcription inhibitor that 
sequesters P-TEFb in an inactive complex (259). The displacement of 
HEXIM1/7SK snRNP from CDK9 leads to upregulation of P-TEFb activity to 
promote RNA polymerase II elongation. The functional interplay between JMJD6, 
transcriptional regulators, and RNA processing factors would be an interesting 
topic for future research.  
 
 Another emerging question from the present research is how JMJD6 is 
involved in the post-transcriptional regulation of C/EBPβ and C/EBPδ. One might 
hypothesize that JMJD6 affects the formation and nuclear export of the mRNPs. 
JMJD6 interacts with U2AF65 and SR proteins (151,159,229). These proteins are 
not just splicing factors but also the adaptors for recruiting the transcription/export 
complex (TREX) and export receptor NXF1/TAP to mRNAs (260-262). The data 
showed that Aly/REF, a component of TREX complex, and the export receptor 
NXF1/TAP immunoprecipitates with the Flag-tagged JMJD6 from the NIH3T3 cell 
extracts (Figure A3). This suggests that JMJD6 associates with the conserved 
RNA export machinery. Further studies are required to examine whether depletion 
of JMJD6 can cause a general defect in RNA export or whether a defect only 
occurs on specific RNAs. The biological significance of the interaction between 
JMJD6 and RNA export proteins also need to be determined.  
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Although two distinct enzymatic functions were assigned to JMJD6, the 
data presented in this thesis suggests that JMJD6 has an additional role 
independent of its enzymatic activity. JMJD6 regulates gene expression via 
multiple mechanisms, and that is likely to link transcription to RNA processing and 
translation. The role of JMJD6 in cellular differentiation is clearly not limited to 
adipocytes, because the JMJD6 knockout mice exhibit defective differentiation in 
multiple tissues (154-156,263). In addition to its role in differentiation, JMJD6 
regulates cell proliferation. Knockdown of JMJD6 slowed proliferation of 
C3H10T1/2 and NIH3T3 cells (Figure A4), which is consistent with other studies 
using different cell types (157,264,265). Therefore, JMJD6 is a critical gene 
expression regulator for both cellular differentiation and proliferation, which might 
explain why the deletion of JMJD6 causes wide spread defects in mice. Finally, 
the enzymatic activity of JMJD6 remains a puzzling question in the field. More 
efforts are required to clarify the enzyme activities and the biological relevance of 
JMJD6 catalytic functions. 
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Appendices 
Table A1 List of primers 
Primers for cloning  Sequence 5’ to 3’ 
shCtrl forward GATCCTGGCGGCGAGTGAAGTACGTGATAAGT 
GTGCTGTCCTTATCACGTACTTCACTCGCCGCC 
ATTTTTGGAAA 
shCtrl reverse AGCTTTTCCAAAAATGGCGGCGAGTGAAGTAC 
GTGATAAGGACAGCACACTTATCACGTACTTC 
ACTCGCCGCCAGG 
shGFP forward GATCCCGAAGCAGCACGACTTCTTCGTGTGCTG 
TCCGAAGTCGTGCTGCTTCTTTTTGGAAA 
shGFP reverse AGCTTTTCCAAAAAGAAGCAGCACGACTTCTT 
CGGACAGCACACGAAGAAGTCGTGCTGCTTCGG 
shJ6-2 forward GATCCCCGATGAACCACAAGAGCAAGTGTGCT 
GTCCTTGCTCTTGTGGTTCATCGTTTTTGGAAA 
shJ6-2 reverse  AGCTTTTCCAAAAACGATGAACCACAAGAGCA 
AGGACAGCACACTTGCTCTTGTGGTTCATCGGG 
shJ6-3 forward GATCCCGCTGACACCCAGAGAACAAGTGTGCTG 
TCCTTGTTCTCTGGGTGTCAGCTTTTTGGAAA 
shJ6-3 reverse  AGCTTTTCCAAAAAGCTGACACCCAGAGAACAA 
GGACAGCACACTTGTTCTCTGGGTGTCAGCGG 
pBABE-JMJD6  
forward 
CCCGGATCCCTCACGATGAACCACAAGAGCAAG 
pBABE-JMJD6 reverse CGGTCGACTTATCATTTGTCATCGTCGTCCTTGT 
AGTCCCTGGAGGAGCTGCGCTC 
pcDNA3.1-JMJD6 
forward 
same as pBABE-JMJD6 
pcDNA3.1-JMJD6 
reverse 
CGAAGCTTTTATCATTTGTCATCGTCGTCCTTGTA 
GTCCCTGGAGGAGCTGCGCTC 
pcDNA3.1-HIF1AN 
forward 
CCCGAATTCGTAGAGATGGCGGCGACGGCAGCC 
pcDNA3.1-HIF1AN 
reverse 
CGAAGCTTTTATTATTTGTCATCGTCGTCCTTGT 
AGTCGTTGTAACGGCCTTTAAT 
JMJD6 H187AD189A 
forward 
GCGTTCTGGAACTGGGATTGCCATCGCCCCTCT 
GGGG 
JMJD6 H187AD189A 
reverse 
CCCCAGAGGGGCGATGGCAATCCCAGTTCCAGA 
ACGC 
GST-JMJD6 2-414 
forward 
GCGGATCCAACCACAAGAGCAAGAAGCGCATC 
GST-JMJD6 2-414 
reverse 
CCCAAGCTTTTATTTGTCATCGTCGTCCTTGTAG 
TCCCTGGAGGAGCTGCGCTCTTTGCT 
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Primers for qPCR Sequence 5’ to 3’ 
Jmjd6 forward GAGCGCCTCAAAAGGAAATA 
Jmjd6 reverse TGGGCACCTTGTAGTCTTCC 
Pparγ2 forward GCATGGTGCCTTCGCTGATGC 
Pparγ2 reverse AGGCCTGTTGTAGAGCTGGGT 
Cebpα foward CCGGCCGCCTTCAACGAC 
Cebpα reverse CTCCTCGCGGGGCTCTTGTTT 
Cebpβ forward TGGACAAGCTGAGCGACGAG 
Cebpβ reverse TGTGCTGCGTCTCCAGGTTG 
Cebpδ forward TTCAGCGCCTACATTGACTC 
Cebpδ reverse TGTGGTTGCTGTTGAAGAGG 
Srebp1c forward AGCTGTCGGGGTAGCGTCTG 
Srebp1c reverse GAGAGTTGGCACCTGGGCTG 
Fasn forward CGTGTTGGCCTACACCCAGAGCT 
Fasn reverse GGCAGCAGGGCCTCCAGCACCTT 
Fabp4 forward GCGTGGAATTCGATGAAATCA 
Fabp4 reverse CCCGCCATCTAGGGTTATGA 
AdipoQ forward CAGTGGATCTGACGACACCA 
AdipoQ reverse CGAATGGGTACATTGGGAAC 
5S rRNA forward GTCTACGGACATACCACCCTG 
5S rRNA reverse TACAGCACCCGGTATTCCCAG 
Primers for ChIP  Sequence 5’ to 3’ 
Pparγ2  -9.5kb forward TTCTTCCCAGTAGGAACTGCAT 
Pparγ2  -9.5kb reverse GATCACTCAGTTGGCATTTCTC 
Pparγ2 -0.3kb forward TGGCCAAATACGTTTATCTGG 
Pparγ2 -0.3kb reverse CCAGTGACCCACACATTCACTG 
Pparγ2 TSS forward ATTCCCACCTCTCCCAAATA 
Pparγ2  TSS reverse GCTCTGGGTCAACAGGAGAA 
Pparγ2  +20kb forward CGAGTCTGTGGGGATAAAGC 
Pparγ2  +20kb reverse CCAAAACAACTCCCCACAAC 
Pparγ2  +96kb forward CTTGGGAGCTACAGCCTTGTG 
Pparγ2  +96kb reverse GCTGTGGTGAAACGACAGTTATTA 
Pparγ2  +100kb forward CCGGGCTCCCTAGATGTAGAC 
Pparγ2  +100kb reverse ACCCTTTCTGAGCGACAACCT 
Cebpα -0.3kb forward CTCCCTAGTGTTGGCTGGAA 
Cebpα -0.3kb reverse GGTGAGTGGGGAGCATAGTG 
Cebpα TSS forward GCCCGACCCTCTATAAAAGC 
Cebpα TSS reverse GGCTCCACCTCGTAGAAGTC 
Cebpα +2.2kb forward GCAGTGTGCACGTCTATGCT 
Cebpα +2.2kb reverse AGCCCACTTCATTTCATTGG 
Cebpα +8kb forward CACAGTGTCTGCTCGCTGTT 
Cebpα +8kb reverse ATTACAGTGCCGCCAGGTAG 
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Cebpα +37kb forward CCCCAATCTTCCCTCAAATGA 
Cebpα +37kb reverse GGAGCCCGGAACCAGAA 
Cebpβ -0.4kb forward CGTGTAGCTGGAGGAACGAT 
Cebpβ -0.4kb reverse CTCGGGAACACGGAGGAG 
Cebpδ -0.1kb forward AGGAGGGAAGGCAAGGAGT 
Cebpδ -0.1kb reverse CTTTTCTAGCCCCAGCTGAC 
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Figure A1.  
      
Figure A1. Evaluation of the specificity of JMJD6 antisera and antibodies. 
Representative western blots probed with (A) the JMJD6 antisera, (B and C) the 
commercial antibodies for JMJD6, and (D) the commercial antibody for HIF1AN, a 
different JmjC protein. JMJD6 and HIF1AN proteins were in vitro translated from 1 
µg of the pcDNA3.1(-) plasmids encoding either FLAG-tagged mouse JMJD6 or 
HIF1AN using a TNT Quick coupled Transcription/Translation Systems (Promega) 
according to the manufacturer’s instructions. 15 µl of the in vitro translated mixture 
was run on 10% SDS-PAGE and Western blotting was performed. (E) 
Representative western blots for JMJD6 and HIF1AN expression in the 24 h post-
transfected C3H10T1/2 cells. 2 µg of the pcDNA3.1(-) plasmids encoding either 
FLAG-tagged mouse JMJD6 or HIF1AN, or the empty vector were transiently 
transfected into C3H10T1/2 cells using Lipofectamine 2000 according to the 
manufacturer’s instructions. 20 µg of the total cell lysate was run on 10% SDS-
PAGE for electrophoresis and Western blotting. β-ACTIN was probed as a loading 
control. Red asterisks indicate the bands corresponding to the target monomer 
and oligomeric proteins. 
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Figure A2.  
 
Figure A2. Over-expression and knockdown of JMJD6 has no effect on 
symmetrical dimethylation of histone H4R3. 
(A) NIH3T3 cells were transfected with the pcDNA3.1 plasmid encoding Flag-
tagged wild type JMJD6 (B) The pBABE empty vector and the construct encoding 
FLAG-tagged wild type JMJD6 (JMJD6-wt) were introduced into NIH3T3 cells by 
retroviral infection. (C) The scramble control (shCtrl) construct and the lentiviral 
shRNA constructs (shJ6-2 and shJ6-3) were introduced into NIH3T3 cells by 
lentiviral infection. The protein extracts were analyzed by western blot with the 
antibodies as indicated. (n=1) 
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Figure A3.  
        
Figure A3. JMJD6 interacts with the proteins involved in RNA splicing and 
nuclear export.  
The pBABE empty vector, the construct encoding FLAG-tagged JMJD6 (J6), and 
the construct encoding FLAG-tagged JMJD4 (J4) were individually introduced into 
NIH3T3 cells by retroviral infection. The protein extracts were subjected to 
immunoprecipitation using M2-beads (Sigma). After washing with the buffer 
containing either 300 mM or 500 mM NaCl, the interacting proteins were eluded 
and analyzed by western blot. The blots were probed with the antibodies as 
indicated. (n=1)  
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Figure A4. 
                           
Figure A4. Knockdown of JMJD6 slows cell proliferation. 
The scramble control (shCtrl) construct and the lentiviral shRNA constructs (shJ6-
2 and shJ6-3) were introduced into (A) NIH3T3 and (B) C3H10T1/2 cells by 
lentiviral infection. 1x105 cells were seeded in 6-well plates. The cells were 
counted at the day as indicated. (SEM, n=3) 
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